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Executive summary
Injectable contraceptives are associated globally with low failure rates but lower continuation rates than 
such other methods as the oral contraceptive pill and intrauterine contraceptive device (IUCD). Injectable 
contraceptives, notably depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN), 
have been approved for commercial sale in India by the Drugs Controller General of India, and it is DMPA 
that is the method used in India. However, injectable contraceptives have not been provided in the basket 
of contraceptive methods available under the Reproductive and Child Health programme in India, largely 
because of fears expressed about their appropriateness for women in India and the quality of services. As such, 
injectable contraceptives are available only through private or social marketing channels, because of which their 
use is limited.
Against this background, the Population Council undertook research to shed light on the feasibility and 
acceptability of making injectable contraceptives more widely available to women in India. The study focused 
on injectable contraceptive users, new method adopters and health care providers drawn from the facilities of 
a range of reproductive health NGOs, including the Family Planning Association of India, Janani, Parivar Seva 
Sanstha and Population Health Services (India). The facilities were drawn from both urban and peri-urban 
areas of several states, namely, Bihar, Delhi, Jharkhand, Madhya Pradesh and Maharashtra, and were selected 
purposively on the basis of the volume of injectable contraceptive users served by each clinic in the two years 
preceding the study. A total of 27 facilities were selected for the study.
The study assessed these issues from three perspectives. A retrospective survey was conducted that followed 
up a total of 375 women who had adopted injectable contraceptives at any time at least 12 months prior to 
the interview in the participating facility, in order to assess the experiences of injectable contraceptive users, 
including the decision-making process; use histories; discontinuation and switching, and factors underlying 
discontinuation; side effects experienced and the acceptability of these side effects; the quality of care received, 
including whether the counselling and information provided were comprehensive and follow-up appropriate, 
and the overall acceptability of the method. Second, a survey of 117 women seeking contraception was 
fielded that assessed, through exit interviews, women’s awareness of injectable contraceptives; contraceptive 
information provided by the health care provider, including whether injectable contraceptives had been offered; 
the method selected and reasons underlying acceptance or non-acceptance of injectable contraceptives. Third, 
in-depth interviews were held with 16 health care providers to draw out health care provider perspectives 
about the advantages and disadvantages of injectable contraceptives, the experiences of women using 
injectable contraceptives, the kinds of counselling and follow-up provided to women who adopted injectable 
contraceptives, and the extent to which health care providers would advocate the inclusion of injectable 
contraceptives in the public health programme.
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Summary
There is a demand for injectable contraceptives
Exit interviews with women seeking to adopt contraception revealed that nine percent of women seeking 
contraception at study facilities, that is, about one-fifth of those opting for a non-terminal method, had 
adopted injectable contraceptives. We acknowledge that the NGO facilities in which the study was located 
were well known for offering injectable contraceptives; and hence their clientele may not be representative 
of all women seeking to adopt contraception more generally. Nevertheless, findings demonstrate that there is 
clearly a demand for injectable contraceptives in diverse settings in India.
A number of factors inhibited women seeking contraception at study facilities from 
adopting injectable contraceptives
Findings suggest a number of factors underlying the relatively limited adoption of this method. Among 
women seeking contraceptive services, many of those who had not intended to adopt injectable contraceptives 
were unaware of the method. Indeed, two-thirds of those who had adopted other methods reported that they 
were unaware of the availability of injectable contraceptives. As most women adopted the method they had 
intended to adopt prior to visiting the facility on the day of the interview, this lack of general awareness 
is likely a key factor inhibiting the use of injectable contraceptives. Women who had adopted injectable 
contraceptives advanced other reasons such as fear of side effects, and the cost of injectable contraceptive 
repeat doses. In addition, the need to access the facility for repeat doses of injectable contraceptives was 
perceived as a serious disadvantage by many; in comparison, they noted that the IUCD did not require 
repeated follow-up and oral contraceptives could be easily purchased or obtained from facilities and outlets 
closer to home.
Experience of side effects was widespread among injectable contraceptive users
As other studies have observed, more than four in five women who adopted injectable contraceptives had 
experienced at least one side effect, largely menstrual disturbances or backache, weakness and weight gain. 
However, of women who had continued using injectable contraceptives for three or more doses, a comparison 
of side effects experienced following the first and third or higher order dose, suggested that side effects, 
notably heavy bleeding and irregular menstrual cycles were considerably less likely to be experienced following 
subsequent doses compared to following the first dose. In all, about three-fifths of all women who experienced 
a side effect had complained about it to a health care provider and about half noted that the side effect 
affected their ability to perform their household responsibilities, both in terms of physical inability to perform 
routine tasks and in terms of the cultural proscriptions forbidding women to enter the kitchen, perform pujas 
or visit a place of worship during menstruation. Indeed, women who had experienced three or more side 
effects were more likely than other women to so report; women who experienced menstrual disturbances were, 
on average, less likely to have complained and less likely to have reported that the side effect had affected 
their ability to perform their household responsibilities than were those who had experienced other side effects.
xi
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Method continuation was limited
Conforming with the thrust of available evidence, both global and from India, our findings suggest that 
method continuation was limited. Life table continuation rates suggest that many women discontinued using 
the method after the first injection, and by 12 months, just 23 percent were continuing to use injectable 
contraceptives. Reasons for discontinuation centred largely around the side effects experienced, with two-
thirds of all those who had discontinued using injectable contraceptives, citing a health-related factor, largely 
menstrual disturbances, as the reason. Many fewer cited method-related reasons (that they planned to switch 
to another method, did not like the method, had doubts about it, needed a break from it or that it was 
inconvenient to use), difficulties in accessing supplies, and fertility-related reasons (that they wanted to become 
pregnant, were infecund or did not engage in sexual relations regularly); one woman reported use failure. 
That side effects were a central reason for discontinuing injectable contraceptive use was evident from findings 
suggesting that life table continuation rates were considerably lower among those who experienced both 
menstrual disturbances and other side effects than among those who experienced just menstrual disturbances.
Continuation of use of injectable contraceptives, as assessed by multivariate analysis, was largely associated 
with a number of socio-demographic and use-related factors. The odds that a woman had continued to use 
injectable contraceptives for at least 12 months were greater among younger and better-educated women, 
and those with larger numbers of children at the time of taking the first dose of injectable contraceptives, 
as compared to other women, Notably, they were also greater among those who experienced fewer side 
effects and were provided good quality of care. Also of interest were findings that continuation of injectable 
contraceptives at early stages of use were significantly associated with whether the decision to adopt injectable 
contraceptives was made jointly by the woman and her husband, suggesting that the husband’s role in 
supporting women was important for method continuation at the initial stages of use.
In in-depth interviews, health care providers concurred that the leading reason for discontinuing injectable 
contraceptive use was the experience of side effects, notably menstrual disturbances. Other reasons mentioned 
included the inconvenience of returning to the facility every three months for re-injections and cost. Health 
care providers highlighted that a range of reasons inhibited women experiencing menstrual disturbances from 
continuing to use injectable contraceptives; for example, those experiencing heavy bleeding or irregular periods 
feared that they had a serious disease, those experiencing amenorrhoea feared that they were pregnant, and 
discontinued the method as a result; and cultural practices that forbid menstruating women from entering 
the kitchen or performing religious activities, including visiting a place of worship, prompted women who 
experienced heavy bleeding or irregular menstruation to discontinue using injectable contraceptives because it 
affected their ability to perform these regular tasks. Several health care providers also noted that weight gain 
and the long waiting time to conception following discontinuation of the method were additional reasons for 
discontinuation.
xii
Injectable contraceptives: Perspectives and experiences of women and health care providers in India
Following discontinuation, large proportions of women switched to using a different 
contraceptive method
Following discontinuation of injectable contraceptive use, about three in ten women switched immediately 
to another contraceptive method, a similar proportion switched to another method (including those who 
switched back to injectable contraceptives) after a gap of one to three months, and about two in five women 
did not adopt another method even after a three months gap. Using these two indicators of all-method 
continuation, findings showed 12-month continuation rates of 45 percent and 53 percent, respectively.
In in-depth interviews, health care providers also noted that method switching was common among women 
who discontinued using injectable contraceptives for method-related reasons, and that the two methods to 
which women most commonly switched were tubal ligation and the IUCD.
Counselling was not comprehensive for most women who adopted injectable 
contraceptives
Findings from women who had adopted injectable contraceptives suggest that although the majority had 
obtained information about injectable contraception largely from health care providers, counselling was 
not comprehensive in many instances. For example, while almost all women who had adopted injectable 
contraceptives had been informed about the need for three-monthly re-injections and their cost, and most had 
been informed about how the method works and the fact that it is a non-terminal method, fewer than three 
in five had been counselled about possible side effects, what to do if problems were encountered, and the 
need to return to the health care provider or facility if doubts or problems were experienced.
Exit interviews with women seeking contraception at study facilities suggest that they had similar 
experiences. Few women reported that counselling had encompassed information about injectable 
contraceptives and their advantages and disadvantages. Indeed, just one in four women seeking contraception 
reported that they had been informed about the availability of injectable contraceptives during pre-adoption 
counselling by the health care provider.
Health care provider perceptions, as espoused in in-depth interviews, differed. Health care provider 
narratives suggest that counselling encompassed both the provision of information and an assessment of 
the prospective client’s suitability for injectable contraceptives. Counselling was held to entail the provision 
of such information as the mechanics of the method (how often it must be taken) and the kind of side 
effects that may occur. All health care providers indicated that they informed women about such side effects 
as amenorrhoea and heavy bleeding, and that they should return to the clinic if they experienced these. 
Other side effects were mentioned less frequently (weight gain for example). Several health care providers 
discussed the importance of including the husband in the counselling session, highlighting the link between 
the husband’s involvement and the quality of subsequent method use, and the perception that many women 
would not adopt a method without having discussed it with their husband. All health care providers 
emphasised that the final decision on method use was made by the woman herself, alone or together with her 
husband. Finally, while a number of health care providers noted that poor and poorly educated women found 
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it more difficult than others to comprehend the information provided, and that they may not continue using 
the method because of the high cost of re-injections, the large majority stressed that they would not deny 
injectable contraceptives to poor and poorly educated women.
Women and providers were divided about the acceptability of injectable contraceptives
Overall, women were divided about the acceptability of injectable contraceptives. As many as one quarter of 
all women could not identify a single positive feature, and a slightly larger proportion could not identify a 
single negative feature of injectable contraceptives. Key positive features included that it enabled women to 
control their fertility, that it was long-acting and does not require a daily routine, that it is easy to use and 
that it is safe. Key negative features, as expected, were the menstrual disturbances and other health-related side 
effects caused by injectable contraceptives. Women who had discontinued the method before completing 12 
months of use (three doses or fewer) were more likely than those who had continued using the method for 12 
months or more (at least four doses) to report negative features and correspondingly, were significantly more 
likely to report such positive features as its safety and effectiveness, and its long-acting nature and ease of use 
than were those who had discontinued before completing 12 months of use. Over half of women who had 
used injectable contraceptives as well as the IUCD or oral contraceptive pills (prior to adoption of injectable 
contraceptives or post discontinuation) reported that they preferred to use injectable contraceptives. Leading 
reasons for this preference included its perceived safety, ease of use, long-acting nature and, in comparison to 
oral contraceptive pills, that it does not require a daily routine.
In in-depth interviews, health care providers corroborated many of the issues raised by women who had 
used injectable contraceptives and those seeking to adopt a contraceptive method. Most health care providers 
noted that a number of their clients had adopted injectable contraceptives and that interest in the method 
was frequently expressed. However, they were mixed about their views on the appropriateness of injectable 
contraceptives as a viable method for their clientele. Almost all agreed that it is a safe and effective method, 
but expressed concerns about the side effects of the method. Several health care providers indicated that 
they would recommend the method to only certain categories of women, for example, those who do not 
want another child, or are older. Many noted that menstrual disturbances made injectable contraceptives an 
unattractive option for women, arguing that neither heavy bleeding nor amenorrhoea were acceptable side 
effects for women. A number of health care providers also noted that for women intending to have another 
pregnancy on discontinuation of the method; time to conception was far longer than that associated with the 
IUCD or oral contraceptives. Notably, not a single health care provider acknowledged the appropriateness of 
injectable contraceptives for recently delivered and lactating women.
Notwithstanding these concerns, health care providers were, for the most part, in favour of including 
injectable contraceptives in the national programme in order that the basket of methods available to 
women would increase and provide women with greater choice. However, they argued strongly for certain 
prerequisites, such as comprehensive and sensitive counselling and effective follow-up, for example. A few 
were sceptical; they believed that even with such improvements in the quality of services, few women in India 
would adopt or continue using injectable contraceptives because their side effects, and notably menstrual 
disturbances, would discourage most women for both health and socio-cultural reasons.
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Recommendations
The findings of the study suggest a number of priority areas for action.
Meet the demand for injectable contraceptives by including the method in the basket of 
contraceptives provided in public sector facilities
Findings highlight that there is considerable interest in adopting injectable contraceptives and clearly a demand 
for a safe and effective non-terminal method that allows women to control their fertility confidentially, that 
does not require daily attention and that does not require to be inserted. Relatively low continuation rates 
are associated with injectable contraceptives globally and the finding should not be interpreted as a lack of 
demand. Indeed, the finding that more than one-fifth of all injectable contraceptive users continued the 
method for 12 months reiterates that there exists a demand for the method among certain groups of women. 
At the same time, evidence that many more discontinue injectable contraceptive use and immediately switch 
to a different method, thereby remaining protected against unintended pregnancy, suggests that injectable 
contraceptives play an important role in women’s overall contraceptive strategies. Expanding the basket of 
contraceptives available to women will, therefore, enhance women’s options and enable them to select the one 
whose features most suit their needs.
Include a component of injectable contraceptives in the training offered to a range of 
health care providers
Findings have suggested that health care providers who serve injectable contraceptive users may not be fully 
aware of the advantages and disadvantages of injectable contraceptives, the full range of side effects that 
are and are not associated with injectable contraceptives, and the counselling needs of potential users. It is 
important, therefore, to include a module on injectable contraceptives in the contraception-related training 
offered to a range of health care providers. For example, health care providers must be made aware of the 
appropriateness of injectable contraceptives for women who are recently delivered and lactating. Similarly, they 
should be trained to recognise that injectable contraceptives may satisfy the needs of women at different stages 
of the life cycle, for example, a newly delivered woman who wishes to space her next pregnancy, or a woman 
who is not medically eligible for an IUCD or does not want to have an IUCD inserted but is looking for a 
long-acting method. At the same time, they should be trained to appreciate that for some women, common 
side effects would likely be an intolerable disturbance in everyday life, and hence, should be equipped to 
counsel women so as to enable the woman to arrive at an informed decision about whether or not to adopt 
injectable contraceptives.
Given that a number of women from our study were drawn from rural areas, it is important that training 
for frontline health workers, such as ANMs, ASHAs and AWWs, should also include information about 
injectable contraceptives, how they function and where they can be obtained, as well as basic information 
about potential side effects and how these should be managed.
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Expand awareness of injectable contraceptives at the community level
Findings have confirmed that many women seeking to adopt contraceptives were unaware of injectable 
contraceptives, and at the same time, although the method is not available through the programme, a 
sizeable number of women do indeed opt for it. It is important, therefore, that efforts are made to inform 
communities, and women in particular, about injectable contraceptives, how they function, their cost, and 
where they can be obtained, as well as basic information about potential side effects.
Improve the quality of care and counselling provided to injectable contraceptive users
Findings suggest a disconnect between the views of health care providers on the comprehensiveness of 
counselling provided and women’s views about the comprehensiveness of counselling received from health care 
providers with regard to injectable contraceptives. This disconnect highlights the need for health care providers 
to ensure that women are indeed making an informed choice, that they fully understand the implications of 
likely side effects for their life. Health care providers have acknowledged the importance of including husbands 
in the counselling session, and findings have confirmed that continuation beyond the first dose is indeed 
influenced by the role of the husband in decision-making. Provided that the woman agrees, it is important 
that counselling includes both the woman and her husband and that both are made fully cognisant of possible 
side effects.
As far as counselling is concerned, health care providers must be trained to ensure that counselling 
encompasses the full range of side effects associated with injectable contraceptives, as well as the action that 
the woman should take in case these side effects are experienced; the need to ensure that the woman has 
understood the implications of the method proposed, including injectable contraceptives, must be emphasised. 
For example, women, and their husbands if present, must be informed that amenorrhoea, irregular menstrual 
cycles and heavy bleeding occur to large numbers of injectable contraceptive users, that some women may gain 
weight, and that return to fertility may be slower than in the case of other contraceptives. Counselling sessions 
must also make women feel supported in case side effects are experienced, and emphasise the appropriateness 
of follow-up visits and phone calls in case the woman has concerns. Our finding that continuation rates were 
significantly higher among women who were provided comprehensive counselling underscores the critical role 
that health care providers play in ensuring method satisfaction.
Make special efforts to inform injectable contraceptive users and potential users about 
health-related side effects
Menstrual disturbances and weight gain are common and well-known side effects of injectable contraceptives, 
and return to fertility is typically longer among women who discontinue using injectable contraceptives than 
other methods. Women considering use of the method must be supported in making an informed decision, 
given these three key concerns. Irregular prolonged bleeding, amenorrhoea and/or heavy bleeding occur among 
most users of injectable contraceptives at some point while using the method, and women should be informed 
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about this likelihood and the fact that side effects are typically not harmful. Although injectable contraceptives 
are a reversible method of fertility regulation, women also need to be informed that since the method is long-
acting, it cannot easily be discontinued or removed from the body if a complication occurs or if pregnancy is 
desired. Counselling sessions should be supplemented by pamphlets and easy-to-read materials that highlight 
these side effects, emphasise that they are not harmful, and advise users about the action to take in case they 
are experienced.
Reduce barriers to accessing supplies
Findings have shown that 16 percent of all women who had discontinued using injectable contraceptives 
and between 12 percent and 28 percent of women who had discontinued using the method after various 
doses reported difficulty in accessing re-supplies. The leading access-related barrier was the inconvenience 
of accessing the facility every three months for re-injections. Long distances, limited freedom of movement 
and unavailability of an escort, and time spent in travelling to the facility for re-injections were significant 
deterrent to method continuation. Efforts are needed that enable women to obtain re-injections closer to their 
homes and at reduced cost; the introduction of the method into the programme would go a long way in 
doing so.
Conclusion
In short, findings suggest that there is a demand for injectable contraceptives among women, and that both 
women and health care providers perceive a number of advantages associated with the method. As is well 
known, injectable contraceptives may not suit the lifestyle of many Indian women and our findings have 
confirmed that the method was adopted and was continued for one year or more, by relatively few women. 
Nevertheless, the fact that it was adopted by one in ten women seeking contraception, and was continued for 
one year or more by one in five women who adopted the method, reiterates that for a significant minority 
of women, its advantages exceed its disadvantages on balance. We conclude that there is indeed a demand for 
the method among this minority of women, and that the inclusion of injectable contraceptives in the basket 
of methods offered under the national programme, along with appropriate emphasis on health care provider 
training and on ensuring informed choice, will expand women’s contraceptive choices and help in ensuring 
their reproductive rights.
1Janani, Parivar Seva Sanstha (PSS), and Population 
Health Services (India) (PHSI)], evidence of users’ 
experiences is sparse. Indeed, a search revealed that 
very few studies have focused on the experiences 
of women using injectable contraceptives (see for 
example, Caleb-Varkey et al., 1998; Indian Council 
of Medical Research, 1985; 1990; 2008; United 
Nations Population Fund, India, 2004; Sama, 2003); 
while all of these explored menstrual disturbances, 
such issues as method continuation, method 
switching and acceptability, quality of services and 
provider perspectives on injectable contraceptives 
were infrequently assessed. This lack of evidence 
makes it difficult to evaluate the effectiveness, 
safety and acceptability of the method; inform the 
debate about the feasibility of including injectable 
contraceptives in the programme, and provide 
appropriate counselling for women to enable them to 
evaluate various contraceptive options and make an 
informed choice about which contraceptive method 
to adopt.
Study Objectives
The objective of this report is to shed light on the 
feasibility and acceptability of making injectable 
contraceptives more widely available to women in 
India. It does so from three perspectives. First and 
foremost, it assesses the experiences of injectable 
contraceptive users, including use histories, 
discontinuation and switching and factors underlying 
discontinuation; side effects experienced and the 
acceptability of these side effects; the quality of 
care received, including whether the counselling 
and information provided were comprehensive and 
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Rationale
Injectable contraceptives are associated globally 
with low failure rates but lower 12-month 
continuation rates than such other methods 
as the oral contraceptive pill and intrauterine 
contraceptive device (IUCD) (Vaughan et al., 
2008; World Health Organization, 2010; Ali and 
Cleland, 2010). Injectable contraceptives, notably 
depot medroxyprogesterone acetate (DMPA) 
and norethisterone enanthate (NET-EN), have 
been approved for commercial sale in India by 
the Drugs Controller General of India (Family 
Health International, 2010; Parivar Seva Sanstha, 
2004; Indian Council of Medical Research, 2008). 
However, injectable contraceptives have not been 
provided in the basket of contraceptive methods 
available under the Reproductive and Child Health 
programme in India, largely because of fears 
expressed about their appropriateness for women 
in India and the quality of services (Parivar Seva 
Sanstha, 2004; Sarojini and Murthy, 2005). As 
such, injectable contraceptives are available only 
through private or social marketing channels. As a 
result, the use of injectable contraceptives is limited. 
Indeed, just 0.1 percent of married women in India 
were using injectable contraceptives in 2005–06 
(International Institute for Population Sciences and 
Macro International, 2007).
Although injectable contraceptives have 
increasingly been offered by private and NGO 
facilities, including through the facilities of a number 
of health-serving NGO programmes [for example, 
the Family Planning Association of India (FPAI), 
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follow-up appropriate, and the overall acceptability 
of the method. Second, it assesses the extent to 
which new method adopters opt for the injectable 
contraceptive method and their motivations for 
preferring injectable contraceptives or other methods. 
Third, it sheds light on the perspectives of providers 
of reproductive health services located in facilities 
providing injectable contraceptives, specifically with 
regard to the extent to which they recommend the 
method to their clients, the kind of counselling and 
information they provide, their perceptions about the 
experiences of their clients, and the extent to which 
they would advocate the inclusion of injectable 
contraceptives in the public health programme.
Background
Depot medroxyprogesterone acetate (DMPA) and 
norethisterone enanthate (NET-EN) are progestin-
only formulations that are injected intramuscularly, 
and work primarily by preventing ovulation and 
thickening cervical mucus (Ministry of Health and 
Family Welfare and United Nations Population 
Fund, India, 2005). They are associated with a 
failure rate of less than 0.3 percent with perfect 
use (correctly and consistently), and three percent 
with typical use (Trussell, 2007; World Health 
Organization, 2010). Although used by a tiny 
minority of contraceptive users in India, injectable 
contraceptives are globally the fourth most popular 
contraceptive method; indeed, it is estimated that 
more than 32 million women use the method 
globally (Lande and Richey, 2006) and that it 
is found to be safe and acceptable to women in 
many developing country settings. DMPA is the 
method used in India; it is supplied largely by non-
governmental organisations and the private sector.
Globally, evidence suggests that injectable 
contraceptives are associated with higher rates of 
discontinuation than other methods: for example, 
the United Nations report on levels and trends 
of contraceptive use suggests that 34 percent of 
oral contraceptive users compared to 46 percent 
of injectable contraceptive users had discontinued 
the method during the first 12 months of use 
(United Nations, 2006). Likewise, a recent study 
of data from 23 countries found wide variation 
across countries, but noted that on average, 36 
percent of women using injectable contraceptives 
had discontinued using the method within 12 
months, compared to 28–29 percent of users of oral 
contraceptive pills and condoms and nine percent of 
IUCD users (Ali and Cleland, 2010).
As mentioned earlier, few studies from India 
have explored the perspectives and experiences of 
women who have used injectable contraceptives. 
Available studies have addressed issues relating 
to injectable contraceptive use through both 
qualitative and quantitative designs. The single most 
consistent finding of these studies is the extent to 
which injectable contraceptives are associated with 
menstrual disturbances. A synthesis of findings 
from these studies suggests that three-quarters or 
more women reported menstrual disturbances. For 
example, a multi-centric study of DMPA users in 
Ahmedabad, Vadodara and Hyderabad observed that 
19 percent experienced excessive bleeding, 21 percent 
experienced irregular bleeding or spotting, seven 
percent reported scanty bleeding and 13 percent 
reported amenorrhoea (United Nations Population 
Fund, 2004). A second multi-centric study, covering 
1209 women who were using NET-EN, reported 
that just 19 percent of those observed for the first 
six months of use reported no menstrual disturbance; 
in contrast, eight percent, 52 percent and 20 percent 
reported frequent bleeding, infrequent bleeding and 
amenorrhoea, respectively (Indian Council of Medical 
Research, 2008). In another study, conducted in 
Gujarat, 87 percent of DMPA users reported side 
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effects, most of which were menstrual disturbances 
(Population Council, 2003). Side effects were also 
found to be widespread in a study conducted in 
Uttar Pradesh among 662 DMPA users: at six 
months, 68 percent reported side effects, mainly 
amenorrhoea (36%), scanty periods and spotting 
(22%) and excessive menstrual discharge (7%) 
(Caleb-Varkey et al., 1998). This finding was also 
observed in a study of 80 women who had adopted 
injectable contraceptives from a facility in Karnataka: 
65 percent experienced amenorrhoea and 70 percent 
experienced spotting (Rai, Prabakar and Nair, 2007). 
A study that compared monthly and bimonthly 
injections of two preparations of Norethisterone 
Enanthate among two groups of women found 
that the side effects reported at 12 months were 
bleeding-related (12–15%) and amenorrhoea (4–7%) 
(Indian Council of Medical Research, 1990). 
Likewise, a qualitative follow-up of 50 DMPA users 
in Delhi found that 25, 16 and 12 women had 
experienced amenorrhoea, excessive bleeding and 
irregular bleeding, respectively (Sama, 2003). Studies 
have noted that menstrual disturbances, notably 
amenorrhoea, increased over time: while 61 percent 
of DMPA users experienced menstrual disturbances 
overall, percentages ranged from 77 percent after the 
first dose to 90 percent among those who continued 
to use the method for 10 or more doses (Parivar 
Seva Sanstha, 2004). Other side effects reported by 
women in these studies included weight gain, pain, 
vaginal discharge, hot flushes and weakness (Sama, 
2003; Caleb-Varkey et al., 1998; United Nations 
Population Fund, India, 2004; Parivar Seva Sanstha, 
2004).
Internationally, discontinuation rates associated 
with injectable contraceptives range from 44 
percent (World Health Organization, 2010) to 
56 percent (Vaughan et al., 2008) at 12 months. 
Discontinuation rates observed among the few 
studies in India that have addressed this issue 
vary considerably. Two Indian studies report 
discontinuation rates similar to those observed in the 
international literature. For example, in 2005–06, 
the 12-month discontinuation rate among injectable 
contraceptive users was 53 percent in India (we note 
that the overall percentage of women who had used 
injectable contraceptives was just 0.1%), compared 
to 20 percent among women using the IUCD and 
49 percent among those using oral contraceptive 
pills (International Institute for Population Sciences 
and Macro International, 2007). The two multi-
centric studies that followed women up to 12 
and 24 months, observed that 35–44 percent had 
discontinued use of NET-EN by 12 months (Indian 
Council of Medical Research, 1990; 2008). In 
contrast, other studies noted considerably higher 
discontinuation rates. For example, the study of 
injectable contraceptive users in various settings of 
Uttar Pradesh found discontinuation rates as high 
as 56 percent and 71 percent after the first and 
second dose of DMPA, that is, by three and six 
months, respectively (Caleb-Varkey et al., 1998), the 
assessment of DMPA clients of two NGOs observed 
that as many as 70–80 percent had discontinued use 
at 12 months (Parivar Seva Sanstha, 2004), and the 
facility-based study of DMPA clients in Karnataka 
reported a discontinuation rate of 43 percent at six 
months (Rai, Prabakar and Nair, 2007).
Notwithstanding widespread side effects and high 
rates of discontinuation, the injectable contraceptive 
method was acceptable to many (70–79%), as 
reported in two studies that explored acceptability 
(United Nations Population Fund, India, 2004; 
Indian Council of Medical Research, 2008).
Two studies have addressed the quality of 
care received by injectable contraceptive users. 
Their findings suggest that women were not 
appropriately screened (Sama, 2003) and were not 
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given information about the possible side effects 
and what to do in case of side effects (Population 
Council, 2003; Sama, 2003). For example, in urban 
Gujarat, just 28 percent of 184 DMPA clients were 
informed about the possible side effects of injectable 
contraceptives and 22 percent about what to do in 
case of side effects (Population Council, 2003).
In summary, in India, very few studies have 
focused on injectable contraceptive use. Almost all 
of these were conducted in the 1990s and early 
2000s and suggest varying but low levels of method 
continuation, widespread experience of menstrual 
disturbances, and poor counselling and quality of 
services. Notwithstanding these findings, women 
in a couple of studies reported that injectable 
contraceptives were a convenient and acceptable 
method in principle.
Study Setting
Given the low prevalence of injectable contraceptive 
use in India, a community-based study was not 
feasible. The study therefore followed up injectable 
contraceptive users drawn from the facilities of a 
range of reproductive health NGOs, including the 
Family Planning Association of India, Janani, Parivar 
Seva Sanstha and Population Health Services (India). 
The facilities were drawn from both urban and peri-
urban areas of several states, namely, Bihar, Delhi, 
Jharkhand, Madhya Pradesh and Maharashtra, and 
were selected purposively on the basis of the volume 
of injectable contraceptive users served by each clinic 
in the two years preceding the study. As mentioned 
earlier, the injectable contraceptive DMPA, approved 
by the Drugs Controller of India, is the method 
used in India and, as such, was the injectable 
contraceptive offered to women in our study.
The socio-demographic and reproductive health 
indicators of the study states, presented in 
Table 1.1, highlight the well-known differences 
in socio-demographic indicators between such less 
developed states as Bihar, Jharkhand and Madhya 
Pradesh on the one hand, and better developed 
ones such as Delhi and Maharashtra on the other. 
For example, female literacy rates ranged from 
53–60 percent in the less developed states to 
76–81 percent in the better developed ones; the 
total fertility rate ranged from 3.1–4.0 in Bihar, 
Jharkhand and Madhya Pradesh to 2.1 in Delhi and 
Maharashtra; the infant mortality rate ranged from 
28–30 in Delhi and Maharashtra to 42–62 in Bihar, 
Jharkhand and Madhya Pradesh; and the percentage 
of women reporting skilled attendance at delivery 
ranged from 28–33 percent to 64–69 percent in 
these states, respectively.
The pattern was somewhat different with regard 
to other indicators. The child sex ratio varied 
widely between study states. It was far below the 
national average in Delhi and Maharashtra, well 
above it in Bihar and Jharkhand, and similar to the 
national average in Madhya Pradesh. Contraceptive 
use patterns also varied. Overall contraceptive 
prevalence ranged from 34–36 percent in Bihar 
and Jharkhand to 56 percent in Madhya Pradesh 
and 67 percent in both Delhi and Maharashtra. A 
similar pattern emerged with regard to the unmet 
need for contraception, which ranged from 23 
percent in Bihar and Jharkhand to 8–11 percent in 
Delhi, Madhya Pradesh and Maharashtra. Use of 
modern non-terminal methods was, for the most 
part, limited: it ranged from 5–7 percent in Bihar, 
Jharkhand and Madhya Pradesh, to 12 percent in 
Maharashtra and 33 percent in Delhi. Awareness of 
injectable contraceptives among both women and 
men was considerably more widespread in Delhi 
than in any other state: 81 percent versus 33–66 
percent among women, and 69 percent versus 38–48 
percent among men.
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Study Design
As described above, the study was conducted in 
selected facilities of various reproductive health 
NGOs in India. From these NGOs, a total of 27 
facilities were selected purposively on the basis of 
their records of first-time injectable contraceptive 
clients served during the calendar year 2010. More 
specifically, we perused the monthly reports of all 
NGOs and selected those facilities that reported 
an average of 25 or more first-time injectable 
contraceptive clients over the period March 
to September 2010. The study included three 
components, namely, a survey of first-time injectable 
contraceptive users, exit interviews with women 
seeking contraception, and in-depth interviews with 
contraceptive service providers from participating 
facilities.
Survey of injectable contraceptive users: A 
retrospective study design was employed in which 
women who had initiated injectable contraceptive use 
any time during March to September 2010, at least 
12 months prior to the interview in the participating 
facility, were followed up, to assess their experiences 
with the method. While a prospective design 
has many advantages, for example that it enables 
researchers to obtain experiences on the day of 
method adoption and at regular intervals thereafter, 
and consent procedures are simpler, it is more time-
consuming and costly. Hence, a retrospective design 
was used. In order to assess use patterns, a calendar 
was employed that recorded women’s monthly family 
planning use and pregnancy status/outcomes between 
January 2009 (prior to the adoption of injectable 
contraceptives) and the month of interview, thereby 
covering the periods prior to and following the 
initiation of injectable contraceptive use.
Exit interviews with women seeking contraception: A 
survey of women seeking contraception was fielded 
that assessed, through exit interviews, women’s 
awareness of injectable contraceptives, the method 
selected and reasons underlying acceptance or non-
acceptance of injectable contraceptives.
In-depth interviews with health care providers: 
In-depth interviews with health care providers 
were conducted to draw out provider perspectives 
about the advantages and disadvantages of 
injectable contraceptives, the experiences of women 
using injectable contraceptives, and the kinds of 
counselling and follow-up provided to women who 
adopted injectable contraceptives.
Study samples and coverage
Samples for all three components of the study were 
drawn from among the clients and providers of the 
27 selected facilities. Details are provided in 
Table 1.2.
Survey of injectable contraceptive users: Our study 
design called for a sample size of 360 women who 
had initiated injectable contraceptive use during the 
recruitment period, roughly 12–21 months prior 
to the interview. This number includes inflation to 
take into account a cluster effect, which we assumed 
to be 20 percent. Further, given that the address 
or telephone number provided by many clients to 
the clinic may have been incomplete, inaccurate or 
obsolete (as we were following up on clients who 
had visited the clinic at least 12 months prior to the 
survey), we recognised that follow-up of all listed 
women was unlikely and unrealistic. Indeed, going 
by the experience of previous follow-up studies 
and by personal communications with the NGOs 
providing services, we assumed that as a result of 
loss to follow-up, and, to a much lesser extent, 
refusal to participate in the study, we would be able 
to interview no more than one half to two-thirds of 
clients who had adopted the injectable contraceptive 
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table 1.2
Coverage of the study
State
Number of 
clinics included 
in the sample
Number of injectable contraceptive 
users followed-up and interviewed
Number of 
women seeking 
contraceptive 
services who 
participated in 
exit interviews
Number of in-
depth interviews 
with health care 
providers
Interviewed Response rate
Bihar 12 94 50.5 45 4
Delhi 1 99 43.0 34 1
Jharkhand 7 108 60.7 14 5
Madhya Pradesh 3 23 52.3 4 2
Maharashtra 4 51 50.0 20 4
Total 27 375 50.7 117 16
method 12 or more months prior to the interview. 
Hence, we aimed to make efforts to reach at least 
600 clients in order to ensure a total of at least 360 
interviewed women.
The 27 selected facilities yielded a total of 740 
women who had adopted injectable contraceptives 
between 12 and 21 months prior to the survey and 
whose addresses appeared to be complete. Efforts 
were made to reach all of these 740 women, and 
all those contacted were invited to participate in 
the study. Respondents thus included both those 
who were still using the method at the time of 
interview, as well as those who had discontinued the 
method and were either not using any method, had 
switched to another method, or had taken a break 
and returned to using injectable contraceptives by 
the time of the survey. A total of 375 women were 
successfully interviewed, giving a response rate of 
51 percent. The majority of women (82%) were 
interviewed in their home; a few, 10 percent and 
eight percent, were interviewed telephonically and at 
the facility, respectively.
Exit interviews with women seeking contraception: 
In a secondary component of the study, we 
interviewed women who sought contraceptives from 
the 27 facilities from which our sample of women 
who had adopted injectable contraceptives was 
drawn. For this component of the study, interviewers 
spent two to three days in each facility and 
interviewed all the women who sought contraception 
from that facility, irrespective of the method 
adopted. The exit interviews sought to understand 
the extent to which the health care provider had 
offered the woman the injectable contraceptive 
method, factors underlying the adoption of the 
method finally selected, and, more specifically, why 
the injectable contraceptive method was or was 
not adopted. A total of 117 women who sought 
contraceptive services from the study facilities and 
who agreed to be interviewed participated in the exit 
interviews.
In-depth interviews with health care providers: 
In-depth interviews were held with at least one 
health care provider from each study facility who 
had provided injectable contraceptive services to at 
least 25 women in the 12 months preceding the 
study. A total of 16 in-depth interviews were thus 
conducted, each lasting one to two hours.
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Data collection
Data collection for all three components of the 
study was conducted simultaneously and took place 
between June and November, 2011. Two structured 
instruments were used to collect data from injectable 
contraceptive users, and women seeking contraceptive 
services from study facilities. In-depth interview 
guidelines were used to interview health care 
providers. Almost all interviews were held face-to-
face; some 36 injectable contraceptive users opted for 
a telephonic interview.
The questionnaire for injectable contraceptive 
users was designed to gather background information 
of the women as well as their contraceptive histories 
over the 36 months preceding the interview, a period 
that also covered the 12–21 month period following 
the adoption of injectable contraceptives. As such, 
a calendar was employed, that obtained information 
month-wise about method use, discontinuation, 
method switching, and, if pregnancy occurred, its 
date and outcome. Aside from this, the interview 
probed women’s decision-making process, side effects 
experienced and the acceptability of these side 
effects, reasons for discontinuation, the perceived 
acceptability of injectable contraceptives, the quality 
of care received, including whether counselling 
and information provided were comprehensive and 
follow-up appropriate, factors that posed obstacles 
to the continuation of the injectable contraceptive 
method, and, for those who had experience with 
other contraceptive methods, their assessment of 
the relative advantages and disadvantages of the 
injectable contraceptive method.
The exit interview questionnaire also obtained 
background information of women seeking 
contraceptive services, but focused on a few issues, 
namely, the method adopted on the day of interview 
and other methods that may have been used in 
the past; information provided by the health care 
provider on various methods of contraception; 
factors underlying the final choice of method, 
and specifically for choosing or not choosing the 
injectable contraceptive method, and the quality of 
care that they had received.
Guidelines for in-depth interviews addressed 
such issues as provider perspectives about injectable 
contraceptives; their suitability for different groups 
of women; the experiences of clients who had 
used injectable contraceptives, notably with regard 
to duration of use, side effects and menstrual 
disturbances experienced; severity of and action 
taken for side effects, and the experiences of clients 
who had adopted injectable contraceptives versus 
other contraceptive methods. We also probed aspects 
of quality of care, including, for example, the 
kind of information that they provided to women 
seeking contraceptives, and recommendations on the 
advisability of including injectable contraceptives in 
the basket of methods provided in the public health 
system.
A team of five female interviewers and three male 
coordinators conducted the interviews. While the male 
coordinators did not conduct interviews with women, 
they tracked respondents, facilitated contact between 
respondents and interviewers, and conducted in-depth 
interviews with health care providers. Investigators 
underwent a three-day training programme that 
comprised a combination of classroom sessions and 
mock interviews. Training focussed on interviewing 
methods, the details of the questionnaire, and research 
ethics, with particular reference to this study, and the 
need to maintain confidentiality.
The study instruments were prepared in English, 
translated into Hindi, and pre-tested. In-depth 
interviews were taped, transcribed and translated into 
English.
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Analysis
Data from the survey of injectable contraceptive 
users and of women seeking contraceptive services 
were entered in CSPro 4.0 and analysed using 
PASW statistics 18. Analysis is largely descriptive. 
Life table techniques were used to derive injectable 
contraceptive continuation and discontinuation 
rates. As such, segments of use were employed 
as units of analysis in the construction of the 
life table for discontinuation. A segment is an 
uninterrupted period of use of the method. The 
life table technique allows for the inclusion of both 
complete and incomplete segments (for example, 
those continuing to use the method at the time of 
interview) of use in an analysis and are considered 
to be the most appropriate way of assessing the 
continuity of contraceptive use (Trussell and Kost, 
1987). Segments of use are divided into monthly 
intervals, measured from the time of beginning 
the segment. The construction of life tables for 
discontinuation rates, for example, starts with the 
calculation of month-by-month discontinuation rates. 
These rates are then linked together to obtain a 
cumulative continuation or discontinuation rate over 
a period of time. Although our calendar collected 
histories from January 2009, continuation rates have 
been calculated for the first segment of injectable 
contraceptive use, that is, from the month in which 
injectable contraceptives were adopted (March to 
September, 2010) to the month of interview (June 
to September, 2011). Hence, for example, only the 
first segment of use is considered for women who 
discontinued using the method and then initiated it 
again after some time.
We also compared factors underlying the 
continuation of injectable contraceptive use among 
women who had used the method for at least nine 
months with those who had discontinued using 
the method before that time. Multivariate logistic 
regression analysis was conducted to ascertain 
the relationship between injectable contraceptive 
continuation and a range of socio-demographic and 
use-related factors.
For textual data, a coding scheme was developed 
and transcripts were coded in ATLAS.ti 6.0 using 
this coding scheme. The coded blocks of text 
related to specific themes, for example, negative 
and positive features of injectable contraceptives, 
side effects experienced by clients, content of 
counselling provided to users and potential users, 
and recommendations for the inclusion of injectable 
contraceptives in the national programme. These 
blocks were analysed to capture typical patterns.
Ethical issues and consent procedures
We recognised that in both the survey of injectable 
contraceptive users and of women seeking 
contraception in the selected facilities, serious 
ethical concerns arose. Primary among these was 
the fact that women’s right to confidentiality could 
be violated if the researchers approached women 
directly. Hence, the research team did not make 
the initial follow-up contact with women in both 
surveys. In the case of women who had adopted 
injectable contraceptives 12–21 months earlier, it 
was a staff member of the facility from which the 
woman had obtained her injectable contraceptive 
supplies who made the initial contact. It was the 
responsibility of the facility staff member to describe 
the study—its objectives and procedures—to the 
client, emphasise that neither abortion nor any other 
services would be affected and seek initial consent 
from the woman. In the case of the facility-based 
component, the clinic administrator obtained initial 
consent from all women seeking contraception 
to permit a study interviewer to approach them. 
Once initial consent was provided, a research team 
member approached the client, sought consent once 
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more, and made an appointment to interview her 
at a suitable time and place. Once consent was 
thus obtained, the woman was recruited into the 
study and interviewed. In contrast, a research team 
member shared a detailed consent form with health 
care providers and sought their written consent for 
participating in in-depth interviews.
The study was approved by the Ethics Committee 
of the Family Planning Association of India.
Structure of this report
This report has five main sections apart from this 
introductory chapter. Chapter 2 describes the socio-
demographic characteristics of respondents. Chapter 
3 addresses the perspectives and experiences of 
women who had adopted injectable contraceptives 
12–21 months prior to the interview; it focuses on 
such issues as method discontinuation and switching, 
side effects experienced, reasons for discontinuation 
and method acceptability. Chapter 4 addresses the 
perspectives and experiences of women seeking 
contraception at study facilities; it focuses on the 
method selected and factors influencing the adoption 
of injectable contraceptives or other non-terminal 
methods. Chapter 5 documents the perspectives 
of health care providers, their perceptions of their 
clients’ experiences, the extent to which they 
encourage or dissuade their clients from adopting 
injectable contraceptives, and their recommendations 
about incorporating injectable contraceptives in 
the national programme. Chapter 6 summarises 
the findings of this study and offers programmatic 
recommendations with regard to women’s experiences 
and perspectives on expanding access to injectable 
contraceptives.
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This chapter presents the socio-demographic profile 
of respondents, including both women who had 
adopted injectable contraceptives 12–21 months 
prior to the survey, and those seeking to adopt 
contraception at study facilities during the period of 
the survey.
Table 2.1 presents the socio-demographic 
characteristics of respondents. While most indicators 
are simple percentages, we note that household 
economic status was measured using an index, 
composed of household asset data on the ownership 
of selected durable goods and access to amenities; 
the index was adapted from the household 
standard of living index used in the Youth in India: 
Situation and Needs study (International Institute for 
Population Sciences and Population Council, 2010). 
The index was constructed from the following items, 
with scores assigned as follows: source of lighting 
(2 for electricity, 1 for kerosene, solar light, and 0 
for others); source of drinking water (2 for piped 
water, hand pump, covered well, etc; 0 for others); 
toilet facility (3 for flush toilet, 2 for pit toilet or 
public toilet, and 0 for no facility); 2 each for the 
ownership of a television, refrigerator or land/mobile 
phone, and 0 for none. Scores were cumulated; the 
index therefore ranges from 0 to 13.
Among the 375 women who had used injectable 
contraceptives, Column 2 of Table 2.1 shows that 
82 percent of all respondents were Hindu and 
22 percent belonged to scheduled caste or tribe 
households. Respondents were, on average, 29 years 
ChaPtEr 2
Social and demographic characteristics  
of respondents
old. They were relatively well educated: for example, 
while about one-quarter (26%) had never been to 
school, more than one-third had completed high 
school (36%). Women who had adopted injectable 
contraceptives reported an average score of 9.8 on 
the wealth index (of a maximum of 13). Work 
profiles suggest, moreover, that just 16 percent were 
engaged in wage-earning activities. Almost half of all 
women, 48 percent, resided in nuclear families and 
four percent reported that their husband lived away 
from them for extended periods of time. As far as 
fertility levels are concerned, injectable contraceptive 
users had an average of 2.6 surviving children, with 
two-fifths reporting three or more surviving children.
Among the 117 women seeking to adopt 
contraception (Column 3 of Table 2.1), profiles were 
largely similar. Among this group, 80 percent were 
Hindu and 20 percent belonged to scheduled caste 
or tribe households. On average, respondents were 
aged 28 years, more than two-fifths (44%) had never 
been to school, and just 12 percent were engaged in 
wage-earning activities. As far as household economic 
status was concerned, the average score on the 
wealth index was 8.5 (of a maximum of 13). More 
than two-fifths (44%) resided in nuclear families 
and five percent reported that their husband lived 
away from them for extended periods of time. As far 
as fertility levels are concerned, women seeking to 
adopt contraception had an average of 2.9 surviving 
children, with almost three in five reporting three or 
more surviving children.
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table 2.1
Socio-demographic profile of respondents
Socio-demographic characteristics
Women who had adopted 
injectable contraceptives, 
March-September, 2010
Women seeking to adopt 
contraception, 
June-September, 2011
Number of women 375 117
Age of women (years) (Mean) 28.7 27.9
Education (%)
No education 25.9 43.6
Completed Class 10 or higher 36.0 18.8
Religion (%)
Hindu 82.4 79.5
Muslim 14.4 18.8
Other 3.2 1.8
Caste (%)
Schedules castes 12.0 16.2
Scheduled tribes 9.9 3.4
Other backward castes 48.5 54.7
General 29.6 25.6
Work statusa (%)
Worked for wages in the last year 16.3 12.0
Wealth index (0 to 13) (Mean)  9.8  8.5
Family type (%)
Nuclear: Co-resides with husband/children only 47.5 44.4
Extended/Joint: Co-resides with husband and/or 
other family members 48.3 50.4
Extended/Joint: Lives with other family members, 
but husband lives away for extended periods of 
time 4.3 5.1
Total number of surviving childrena (%)
0 0.8 1.7
1 18.1 6.0
2 41.1 34.2
3 or more children 40.0 58.1
Mean 2.56 2.86
State (%)
Bihar 25.1 40.2
Delhi 26.7 29.1
Jharkhand 28.8 10.3
Madhya Pradesh 6.1 3.4
Maharashtra 13.3 17.1
Total 100.0 100.0
Note: aAt the time of accepting the first dose of injectable contraceptives among women who adopted injectable contraceptives 
during March-September, 2010 and were interviewed retrospectively, and on the day of the interview for women seeking 
contraception.
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We note, finally, that our state-wise distribution 
of respondents varied considerably as a result of our 
purposive sampling design. More than three-quarters 
of both injectable contraceptive users and women 
seeking contraceptive services came from three 
states—Bihar, Jharkhand and Delhi.
The socio-demographic profile of the 16 health 
care providers interviewed in-depth shows that all 
16 were female. They ranged in age from 30 to 78 
years, with four health care providers aged between 
30 and 39 years, six each aged between 40 and 49 
years and 50 years and above. As far as educational 
qualifications are concerned, 14 held MBBS degrees, 
and two held BAMS (Bachelor of Ayurvedic 
Medicine and Surgery) degrees. Finally, most health 
care providers had been practising for extended 
periods of time. Indeed, the median number of 
years during which health care providers had been 
practising was 22 years, ranging from four to 37, 
with just four health care providers reporting that 
they had been practising for less than ten years.
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This chapter explores the experiences of women 
who had adopted injectable contraceptives 12–21 
months prior to the study. It covers a range of 
issues: their sources of information about injectable 
contraceptives prior to adopting the method and 
the decision-making process leading to injectable 
contraceptive use; the duration of use and reasons 
for discontinuation; side effects experienced, their 
severity, and action taken to address them; method 
switching experiences; and acceptability of the 
method, namely, perceptions about its best and worst 
features.
As mentioned earlier, our sample comprised 
women who had adopted injectable contraceptives 
during the period March to September 2010, such 
that the vast majority of women had adopted the 
method 12–21 months prior to the interview, 
although, in a few cases, adoption had taken place 
16–21 months prior to the interview. Almost 
all women who had adopted the method (95%) 
reported that they were issued a card at the time 
of getting the first dose of injectable contraception; 
however, only one quarter (27%) of women 
were able to locate the card and present it to the 
interviewer.
Decision-making process
Women who had adopted injectable contraceptives 
were probed about the source from which they had 
first heard about injectable contraceptives—whether 
prior to adoption of the method or in the course of 
seeking contraceptive services. Findings, presented 
in Table 3.1, suggest that the majority of women 
had heard about injectable contraceptives from a 
health care provider or facility (62%), either in the 
course of seeking contraceptive services, or in the 
course of a previous visit. As many as 46 percent of 
the women had been informed about the method 
by a private sector provider. It is notable, however, 
that although the method is not available through 
the public sector, as many as one in five women 
reported having heard about injectable contraceptives 
from a public sector provider, and specifically a nurse 
or Auxiliary Nurse Midwife (ANM) (15%) and an 
ASHA (Accredited Social Health Activist) or AWW 
(Anganwadi Worker) (5%). In addition to health 
care providers, a large proportion (47%) of women 
reported that they had heard about the method 
from their informal networks, most often a friend or 
neighbour (30%) and/or their husband (10%).
Women were asked, in addition, about which 
contraceptive method or methods they had wanted 
to adopt when they visited the facility to obtain 
contraceptive services. As Table 3.2 suggests, two-
thirds of all injectable contraceptive users had 
planned to adopt injectable contraceptives when they 
arrived at the facility for contraceptive services 12–21 
months earlier, clearly suggesting that many women 
had come to the facility with some prior awareness 
of the method. Nevertheless, about 16 percent 
of all injectable contraceptive users had originally 
ChaPtEr 3
Experiences of women using injectable 
contraceptives
15
Chapter 3: Experiences of women using injectable contraceptives
table 3.1
Source of information among women who had adopted injectable contraceptives: Percentage 
of women who had heard about injectable contraceptives prior to or in the course of seeking 
contraceptive services by source of information
Source of information
Women who had adopted 
injectable contraceptives
Health care provider/facility 62.4
Private doctor/Clinic 45.6
Public sources 20.3
Primary Health Centre 0.8
Community Health Centre 0.3
Nurse/ANM 14.7
ASHA/AWW 5.3
Family, friends and neighbours 46.7
Family members 19.5
Husband 10.1
In-laws/Parents 2.4
Other relatives (aunt/sister-in-law/sister/other) 7.5
Friend(s) and neighbour(s) 29.9
Other
Public campaigns (poster/radio/vehicle announcement) 1.1
Number of women 375
Note: Multiple responses possible.
intended to adopt a different method: nine percent 
had intended to be sterilised and seven percent to 
adopt a different non-terminal method—six percent 
to have an IUCD inserted, and about two percent 
to use oral contraceptives or the condom. Almost 
one-fifth (19%) were undecided about which method 
to adopt when they visited the facility. Among the 
16 percent who had visited the facility intending 
to adopt a specific method other than injectable 
contraceptives, the health care provider had played 
a key role in influencing the adoption of injectable 
contraceptives: one half of these women reported 
that the health care provider had counselled them 
and suggested that the method they had intended 
to adopt was not appropriate for them (50%; not 
shown in table). In a few cases, the woman and/
or her husband had changed their mind after being 
counselled: 12 percent reported that they were afraid 
of the side effects of the method they had originally 
selected, and eight percent reported that their 
husband did not permit her to adopt the method 
they had intended to use (not shown in table).
Table 3.3 presents the role of the woman herself 
and others in the final decision to adopt injectable 
contraception. It is notable that the large majority 
of women (86%) reported that they had made the 
final decision to adopt injectable contraceptives on 
their own, with or without the involvement of other 
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table 3.2
Intended contraceptive method: Percentage of women by contraceptive method they had intended 
to adopt prior to visiting the facility
Intended contraceptive method
Women who had adopted 
injectable contraceptives
Injectable contraceptives* 66.7
Other non-terminal methods 6.9
 Intrauterine contraceptive device 5.6
 Oral contraceptive pill 1.3
 Condom 0.3
Terminal method
 Female sterilisation 8.8
Undecided: no method in mind 19.2
Number of women 375
Note: Multiple responses possible; *64.8 percent reported that they had intended to adopt injectable contraceptives and no 
other method.
table 3.3
Contraceptive decision-making role: Percentage of women by lead decision-maker(s) in the final 
selection of injectable contraceptives
Decision-maker
Women who had adopted 
injectable contraceptives
Health care provider 12.0
 Doctor 11.2
 Nurse 1.2
Self 85.6
Other
 Husband* 62.7
 Mother-in-law  1.3
 Friend, other 0.8
Nunber of women 375
Note: Multiple responses possible; *52 percent made the decision together with wife.
decision-makers. Others participating in the final 
decision included the husband (63%) and a health 
care provider (12%); the mother-in-law and others 
were rarely involved. It is notable that just a little 
over one half (52%) of all women reported that they 
had made the decision jointly with their husband; 
about 11 percent of the women reported that their 
husband had made the final decision without them.
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Injectable contraceptive counselling 
Women were asked about the kind of counselling 
they had received when they opted for injectable 
contraceptives. Findings, presented in Table 3.4, 
suggest that counselling was not comprehensive for 
most women. Almost all reported that they had 
been informed about the three-monthly cycle of 
injectable contraceptives and its cost (98% and 91% 
respectively), 77 percent had been informed about 
how the method works, and two-thirds had received 
an information brochure on the method from the 
health care provider. However, fewer than one 
half had been counselled about other matters: for 
example, just 56 percent had been informed about 
the possible side effects of the method, 34 percent 
about what they should do if they encountered any 
problems or side effects, and 42 percent had been 
informed that they should return to the service 
provider or facility if they had any doubts or 
experienced any problem.
Also of concern was the finding that of those 
informed about side effects, relatively small 
proportions were informed about the range of 
side effects experienced, in general, by women 
using injectable contraceptives. Hence, as seen in 
Table 3.5, of the 148 women counselled about 
side effects, fewer than two-thirds (63%) were told 
about the possibility of experiencing amenorrhoea, 
less than half about the possibility of experiencing 
heavy bleeding (47%), and 35 percent about the 
possibility of experiencing irregular periods. Few 
women reported being told about other side effects: 
spotting (12%), weight gain (16%), backache (4%) 
and weakness (5%). Given the large proportion 
of women who experienced side effects, it is of 
concern that so few were informed about the links 
between injectable contraceptive use and menstrual 
disturbances, in particular.
table 3.4
Injectable contraceptive counselling and information obtained from health care providers
Counselling and information All women
Access to written materials
Received a brochure on injectable contraceptives from the health care provider 68.0
Had seen a poster on injectable contraceptives at the facility 44.8
Information provided about
How injectable contraceptives work 77.3
The non-terminal nature of injectable contraceptives and need for three–monthly follow-up 
visits for repeat injections 98.1
Cost of each injection 90.9
Possible side effects of injectable contraceptives 55.5
Action to be taken if problems or side effects are encountered 33.6
Told to come back to the clinic or contact health worker if she has doubts/side effects 41.9
Number of women 375
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Side effects experienced
Women were asked about the side effects experienced 
after taking each dose of the injectable contraceptive: 
a general question was first posed, asking women to 
spontaneously identify the side effects experienced, 
and this was followed by probing questions that 
inquired about the experience of any other side 
effects that may have been experienced. Table 3.6 
(Column 2) presents women’s experiences as reported 
both in direct questioning and after probing. 
Findings suggest that large proportions of users 
reported the experience of one or more side effects. 
In all, 82 percent reported one or more side effects 
that occurred following the first or subsequent doses 
of injectable contraceptives; three-quarters of these 
women (74%) reported a side effect spontaneously 
(not shown in table). About three-quarters of 
all women (76%) had experienced one or more 
menstrual disturbances: indeed, between one-fifth 
and two-fifths had experienced such disturbances 
as amenorrhoea, heavy bleeding and irregular 
periods. Further, almost all of these women reported 
menstrual disturbances spontaneously (68%; not 
shown in table).
Almost three in five women (58%) reported 
experiences of other side effects related to the use 
of injectable contraceptives, including weakness 
(40%), backache (27%), weight gain (16%) and 
anxiety or stress (15%). A large proportion of 
women reporting such other side effects also did so 
spontaneously (38%, not shown in table). We note 
that the majority of women who reported other 
side effects also reported one or more menstrual 
disturbances. Indeed, just 22 women (about 10% 
of women reporting other side effects) did not also 
report menstrual disturbances. Of these 22 women, 
13 reported weakness, six reported weight gain, four 
reported backache, three reported weight loss, two 
reported anxiety or stress and three reported swelling, 
pain and so on (not shown in table).
Columns 3 and 4 of Table 3.6 show the extent 
of side effects experienced by women who had 
discontinued after the first or second dose, and 
those who had continued for three or more doses 
of injectable contraceptives, respectively. Overall, 
similar proportions of women in both groups 
reported one or more side effects. Findings further 
show that while similar proportions of women 
table 3.5
Information provided by health care providers about side effects: Percentage of women who were 
informed about possible side effects of injectable contraceptives by type of side effect discussed
Side effects Women who were informed about side effects
Heavy bleeding 46.6
Spotting between menstrual periods 12.2
Irregular periods 35.1
Amenorrhoea 62.8
Backache 4.1
Weakness 4.7
Weight gain 16.2
Number of women 148
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in both groups had experienced one or more 
menstrual disturbances, women who continued 
using injectable contraceptives beyond the second 
dose were significantly less likely than shorter-term 
users to report such menstrual disturbances as heavy 
bleeding and irregular periods, and significantly 
more likely to have experienced amenorrhoea. Other 
side effects were slightly more likely to have been 
experienced by women who had discontinued using 
the method after the first or second dose compared 
to longer-term users; indeed, longer-term users were 
significantly less likely to report weakness, weight 
loss and anxiety or stress than shorter-term users, but 
were significantly more likely to report weight gain.
In order to assess the extent to which the 
experience of side effects diminished with subsequent 
doses of injectable contraceptives, we explored 
experiences after each dose among women who had 
continued to use the method for three or more 
doses. Findings show a mixed picture (Columns 5, 
6 and 7 of Table 3.6). The experience of menstrual 
disturbances fell consistently but mildly with 
continued use of injectable contraceptives—from 
47 percent after the first dose to 35 percent after 
the third dose, with proportions experiencing such 
side effects as heavy bleeding declining significantly 
between the first and second doses, while the 
experience of amenorrhoea declined modestly. 
Experiences of other side effects suggest that overall, 
reporting of side effects increased significantly in the 
period between the first and second doses, and fell 
significantly thereafter, but experiences of individual 
side effects varied considerably. For example, there 
was a significant increase in the experience of 
weight gain, self-reported foul smelling vaginal 
discharge and swelling of feet and hands between 
the first and second doses, which then levelled off or 
declined marginally thereafter. At the same time, the 
experience of weakness and back pain increased more 
modestly between the first and second doses, and 
also levelled off thereafter.
In order to better understand the action taken 
by women who experienced various side effects, 
women who had experienced a particular side effect 
were asked whether they had complained about 
it to a health care provider. Findings reported in 
Table 3.7 suggest that overall, some 62 percent of 
all women, and 59–60 percent of those experiencing 
any menstrual disturbance or any other side effect, 
had brought their side effect to the attention of a 
health care provider. Among women experiencing 
different types of side effects, those who had 
experienced menstrual disturbances together with 
other side effects, and those reporting three or more 
side effects were most likely to have complained to a 
health care provider (80% and 84%, respectively). In 
contrast, fewer women experiencing only menstrual 
disturbances (32%), only other side effects (27%) or 
fewer (one or two) side effects (44%) reported that 
they had complained about their side effect(s) to a 
health care provider.
A roughly similar picture emerged when women 
were also asked whether the side effect(s) had 
affected their performance of regular household 
responsibilities, both in terms of physical inability 
to perform routine tasks and in term of the cultural 
proscriptions forbidding women to enter the kitchen, 
perform pujas or visit a place of worship during 
menstruation. Overall, half (52%) of all women—
ranging from 40 percent of those experiencing 
some menstrual disturbances to 65 percent of those 
experiencing some other side effects—reported that 
the side effect had interfered with the performance 
of their regular household responsibilities. Women 
who experienced both menstrual disturbances and 
other side effects and those who experienced three 
or more side effects, were most likely to report 
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that the performance of their regular household 
responsibilities had been affected. For example, 
71 percent of those who experienced menstrual 
disturbances along with other side effects (most often 
backache, weakness and weight gain), and 82 percent 
of those who experienced three or more side effects, 
reported that the side effect had disturbed their 
performance of household responsibilities, compared 
to 17 percent of those who had experienced a 
menstrual problem without other side effects and 
36 percent of the small number of women who 
had experienced some other side effect without any 
menstrual disturbances.
Method continuation
The study recruited women who had adopted 
injectable contraceptives for the most part, 12–15 
months prior to the interview; a few women were 
included whose first dose of injectable contraceptives 
had been taken earlier, that is, 16–21 months prior 
to the interview. About one half of all women 
reported that they had taken just one dose of 
injectable contraceptives, and just one quarter 
reported taking four or more doses.
Life table method continuation rates were 
measured at the completion of the second, third, 
fourth and fifth doses, that is at six, nine, 12 and 
15 months, respectively, and are presented in 
Figure 3.1. Findings confirm low rates of 
continuation. The continuation rate after six months 
was just 51 percent, and fell to 37 percent, 23 
percent and 15 percent at nine, 12 and 15 months, 
respectively.
table 3.7
Of women experiencing at least one side effect, percentages reporting that they had complained 
to a health care provider about the side effect and that the side effect had affected their ability to 
perform household work
Side effect(s) experienced
Women who had 
complained to a health 
care provider about the 
side effect
Women whose side 
effect affected the 
performance of 
regular household 
responsibilities
Number of injectable 
contraceptive users who 
experienced the side 
effect
Any side effect 62.4 52.3 306
Any menstrual disturbance 58.8 40.1 284
Any other side effect (other than 
menstrual disturbance) 59.7 64.8 216
One or two side effects 43.9 26.8 164
Three or more side effects 83.8 81.7 142
Specific side effects
Only menstrual disturbances, no 
other side effects 32.2 16.7 90
Only other side effects, no 
menstrual disturbances 27.3 36.4 22
Both menstrual disturbances and 
other side effects 80.4 70.6 194
Note: Multiple responses possible.
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Use failure
In one case, the woman reported that she was late 
for her re-injection and had become pregnant during 
this period, thus giving a typical use failure rate of 
0.3 percent.
Reasons for discontinuation
The 329 women who had discontinued the use of 
injectable contraceptives any time up to the time of 
the interview were probed about their reasons for 
discontinuation. Findings, presented in Table 3.8, 
suggest that, as observed in previous studies, the 
reasons for discontinuation centred largely around 
the side effects experienced. Some 65 percent of 
all those who had discontinued the method cited 
a health-related reason for doing so. The leading 
side effect, again as noted in other studies, was 
menstrual disturbances. In total, more than half of 
all users (53%) reported that they had discontinued 
using injectable contraceptives because of irregular 
menstruation, heavy bleeding or amenorrhoea 
associated with method use. In addition, some 37 
percent reported such other side effects as vaginal 
discharge, swelling of hands and feet, itching, pain 
and weight gain. The second most often cited cluster 
of reasons for discontinuation was method-related: 
some 20 percent reported that they had planned 
to switch to another method, did not like the 
method, had doubts about it, needed a break from 
it or that the method was not convenient to use. A 
third group of reasons were access-related, centring 
around difficulties in accessing supplies: 16 percent 
cited these reasons, mostly concerning difficulties in 
reaching the facility to obtain subsequent doses of 
injectable contraceptives. Finally, some 10 percent 
of those who had discontinued cited fertility-related 
reasons: in order to become pregnant or because they 
Figure 3.1 Life table continuation rates of injectable contraceptives at the completion of each 
tri-monthly dose
Note: Eleven women who returned for a subsequent dose of injectable contraceptives three or more months after the scheduled appointment 
for re-injection, have been treated as having discontinued the method.
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table 3.8
Factors underlying discontinuation: Percentage of women who discontinued use of injectable 
contraceptives by dose after which the method was discontinued and reason(s) for discontinuation
Reasons for discontinuation
All women 
who had 
discontinued 
injectable 
contraceptive 
use
Women who discontinued injectable 
contraceptive use by dose after which the 
method was discontinued
1st 
dose
2nd 
dose
3rd 
dose
4th–8th 
doses
Health-related reasons 65.0 70.5 59.3 62.7 51.2
a. Menstrual disturbances 52.6 61.7 35.2 49.0 39.0
Irregular menstruation 18.5 21.3 16.7 13.7 14.6
Heavy bleeding 18.8 25.7 11.1 9.8 9.8
Amenorrhoea 24.3 25.7 13.0 35.3 19.5
b. Other 37.4 38.8 42.6 33.3 29.3
Negative effect on health (includes infection, white 
discharge, swelling in hands and feet, itching, 
abdominal pain, weight gain) 37.4 38.8 42.6 33.3 29.3
Method-related reasons 20.4 19.7 14.8 17.6 34.1
Planned to switch to another method 9.4 9.3 3.7 5.9 22.0
Did not like the method 3.6 4.4 3.7 0.0 4.9
Not convinced/Had doubts about injectable 
contraceptives 8.2 8.2 7.4 11.8 4.9
Needed a break from injectable contraceptive use 1.2 0.0 0.0 2.0 7.3
Method not convenient to use 0.3 0.0 1.9 0.0 0.0
Access-related reasons 16.1 13.7 27.8 15.7 12.2
Difficulty in reaching the facility 13.4 12.0 20.4 13.7 9.8
High cost of injectables 1.8 1.6 3.7 0.0 2.4
Health care provider not easily accessible 0.6 0.0 1.9 2.0 0.0
Injectable contraceptives were not available at the 
clinic 0.9 0.5 3.7 0.0 0.0
Fertility–related reasons 10.3 10.4 7.4 13.7 9.8
Planning a pregnancy 4.9 3.8 3.7 5.9 9.8
Not having sex/Infrequent sex/Husband away 5.2 6.6 1.9 7.8 0.0
Menopausal/Had a hysterectomy 0.6 0.0 1.9 2.0 0.0
Use failure 0.3 0.5 0.0 0.0 0.0
Number of discontinuers 329 183 54 51 41
Note: Multiple responses possible.
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were infecund or not engaging in sexual relations 
regularly. As noted above, one woman reported use 
failure as a reason for discontinuation.
What is notable is that irrespective of the 
duration of use of injectable contraceptives, 
menstrual disturbances remain the leading reason 
that women attributed to discontinuation of the 
method. At the same time, there is an inverse 
association between duration of use and reported 
discontinuation attributed to menstrual disturbances: 
from 62 percent after the first dose to 39 percent 
after the fourth or subsequent dose. Other reasons 
for discontinuation did not vary as widely. For 
example, other side effects were reported to have 
influenced discontinuation for 39 percent of users 
who discontinued after the first dose, as compared 
to 29 percent of those who discontinued after the 
fourth or subsequent dose. Other reasons were 
typically cited by fewer women and do not show 
a consistent pattern over the period of use. For 
example, method-related reasons were cited by 
15–20 percent among those who discontinued 
after the first, second and third doses, respectively, 
but increased to 34 percent thereafter. Fertility-
related reasons ranged from 14 percent to seven 
percent, while access-related reasons increased 
from 14 percent to 28 percent among those who 
discontinued the method after the first and second 
doses, and fell to 12 percent among those who did 
so after the fourth or subsequent dose.
Figure 3.2 shows life-table continuation rates 
among women who had adopted injectable 
contraceptives, by side effects experienced: notably, 
any side effect, menstrual disturbances without any 
other side effect, and both menstrual disturbances 
and some other side effect (small numbers prevented 
Figure 3.2 Life table continuation rates of injectable contraceptives at the completion of each 
tri-monthly dose by side effects experienced
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us from conducting the same exercise among 
those who experienced only other side effects). 
Continuation rates were largely similar up to six 
months of method use. Thereafter, differences 
emerged. Continuation rates were somewhat higher 
among those who experienced only menstrual 
disturbances than among those who experienced 
both menstrual disturbances and other side effects. 
For example, at nine months, 42 percent of those 
experiencing only menstrual disturbances had 
continued using the method compared to 34 percent 
of those experiencing both menstrual disturbances 
and other side effects; corresponding percentages 
were 27 percent and 18 percent, respectively, at 
month 12; 22 percent and 10 percent, respectively, 
at month 15; and 18 percent and 6 percent, 
respectively, at month 18.
Method switching
A large proportion of women who had discontinued 
the use of injectable contraceptives switched to a 
different method, as evident from Table 3.9. Almost 
one-third (31%) of discontinuers had switched 
directly to a terminal (5%) or other non-terminal 
(26%) method, and another 29 percent had 
discontinued contraceptive use entirely for more 
than one month, but adopted a terminal (7%) or 
table 3.9
Of women who discontinued use of injectable contraceptives, percentages who had switched 
methods immediately and after a break of one or more months, by method adopted
Contraceptive status of discontinuers
Women who discontinued 
injectable contraceptive use
Discontinued and did not use any contraception 40.4
Discontinued and switched immediately (within a month) to 30.7
Oral contraceptive pills 8.2
Intrauterine contraceptive device 1.8
Condom 11.9
Female sterilisation 4.9
Periodic abstinence 3.0
Withdrawal 0.9
Discontinued and switched later (between one and three months) to 28.9
Injectable contraceptives 3.3
Oral contraceptive pills 7.0
Intrauterine contraceptive device 1.2
Condom 6.4
Female sterilisation 7.0
Periodic abstinence 3.3
Withdrawal 0.6
Number of discontinuers 329
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other non-terminal (22%) method thereafter. Indeed, 
three percent of discontinuers opted to return to 
the method after a one- to three-month break. 
Overall, however, 40 percent of women who had 
discontinued method use had not adopted another 
method until the date of the interview; as many as 
10 percent had deliberately discontinued method use 
in order to become pregnant, because they were no 
longer at risk of pregnancy, or because they were not 
having regular relations with their husband.
Given the above profile of method switching, 
we explored all-method continuation rates (Figure 
3.3). In view of the fact that many women switched 
from injectable contraceptives to another method 
without a break, the all-method continuation rate 
is considerably higher than the continuation rate 
of injectable contraceptives. For example, compared 
to a six-month continuation rate of 51 percent 
for injectable contraceptive use, the all-method 
continuation rate was 65 percent; corresponding 
percentages at 12 months were 23 percent and 45 
percent, respectively. We also calculated an all-
method continuation rate that also includes women 
who discontinued injectable contraceptive use for a 
period of one to three months and then switched to 
another method (without becoming pregnant during 
these months); with this definition, the all-method 
continuation rates were 71 percent and 53 percent at 
six and 12 months, respectively.
Acceptability of injectable 
contraceptives
In order to assess the perceptions of injectable 
contraceptive users about the method, we asked 
them to list the positive and negative features of the 
method. As seen in Table 3.10, about three quarters 
of all women identified at least one positive feature. 
Large proportions of women reported, among its 
Figure 3.3 Life table all-method contraceptive continuation rates among women who had adopted 
injectable contraceptives
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table 3.10
Perceived features of injectable contraceptives among all women by duration of injectable 
contraceptive use
Perceived features of injectable 
contraceptives All women
Women who 
discontinued 
injectable 
contraceptive use 
within 12 months 
(three or fewer doses) 
(%)
Women who 
continued injectable 
contraceptive use for 
12 or more months 
(at least four doses) 
(%)
Positive features
Safety 18.9 16.0 28.7***
Enables women to effectively control 
their fertility 38.1 32.6 56.3***
Long-acting, does not require a daily 
routine 34.9 31.3 47.1***
Easy to use 23.7 18.8 40.2***
Reversible 1.3 0.7 3.5**
Can be used confidentially 5.9 6.6 3.5
At least one positive feature 75.2 70.1 91.9***
Negative featuresa  
Heavy bleeding 17.6 20.8 6.9***
Spotting between menstrual periods 4.0 3.8 4.6
Irregular periods 20.8 22.6 14.9*
Amenorrhoea 33.3 34.7 28.7
Backache 6.7 6.6 6.9
Weakness 23.2 25.4 16.1*
Weight gain 12.5 10.4 19.5**
Weight loss 1.3 1.7 0.0
Foul-smelling vaginal discharge 1.6 1.4 2.3
Inconvenient to use 0.8 0.7 1.2
Cost 0.8 1.0 0.0
Difficult to obtain repeat doses 2.1 2.8 0.0
Stomach pain/heaviness 2.1 1.4 4.6*
Body/leg/knee/breast pain and 
breathing problems 3.2 3.5 2.3
Itchiness 0.5 0.7 0.0
At least one negative feature 72.8 77.8 56.3***
Number of women 375 288 87
Note: Multiple responses possible; a0.3 percent reported other reasons, not included in the table; *p<=0.10, **p<=0.05, 
***p<=0.01.
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positive features, that it enabled women to control 
their fertility (38%), that it was long-acting and does 
not require a daily routine (35%), that it is easy 
to use (24%) and that it is safe (19%). Although 
many women identified the positive features of 
injectable contraceptives, almost as many women 
(73%) identified at least one negative feature of 
injectable contraceptives. Among its negative features, 
as expected, were the menstrual disturbances it 
causes: 33 percent reported amenorrhoea, 21 percent 
reported irregular periods and 18 percent reported 
heavy bleeding as its worst feature. Other negative 
aspects included weakness, reported by almost one in 
four women (23%) and weight gain, reported by 13 
percent of the women.
As expected, women who had discontinued the 
method before completing 12 months of use (three 
doses or fewer) were more likely than those who 
had continued using the method for 12 months or 
more (at least four doses) to report negative features. 
For example, 30 percent of the former group, 
compared to eight percent of the latter group could 
not identify a single positive feature of injectable 
contraceptives; conversely, while 22 percent of those 
who had discontinued the method before completing 
12 months of use reported that the method did not 
have any negative features, as many as 44 percent of 
those who had continued for at least 12 months so 
reported. Women who continued using the method 
for at least 12 months were significantly more likely 
to report such positive features as its safety and 
effectiveness, and its long-acting nature and ease 
of use than were those who discontinued before 
completing 12 months of use. Conversely, those who 
discontinued before completing 12 months of use 
were significantly more likely than those who had 
continued using it for at least 12 months to report 
such negative features as heavy bleeding, irregular 
periods and weakness. What is notable is that large 
and similar proportions of both groups reported 
amenorrhoea as a negative feature of injectable 
contraceptives (35% and 29%, respectively), and 
weight gain was significantly more likely to be 
reported by those who had continued using the 
method for at least 12 months than those who had 
used it for shorter periods of time (20% versus 10%).
Additionally, we asked injectable contraceptive 
users who had also used the IUCD and oral 
contraceptive pills, respectively, about their preferred 
method and the reason(s) for such preference 
(not shown in table). Among the 39 injectable 
contraceptive users who had also used an IUCD 
either before adopting or after discontinuing 
injectable contraceptives, 72 percent (28 women) 
said that they preferred injectable contraceptives. 
Leading reasons for this preference included that it 
was safer (57%) and easier to use (57%). Eleven 
injectable contraceptive users, who expressed a 
preference for the IUCD, also said that the IUCD 
was safer (6) and easier (1) to use; other reasons 
included the fact that it is longer-acting (3) and 
reversible (3).
Among the 92 injectable contraceptive users who 
had also used oral contraceptives at some point 
in their contraceptive careers, 53 percent reported 
that they preferred injectable contraceptives because 
they are long–acting, do not require a daily routine 
(78%) and were perceived to be safer (29%). Of the 
43 women who preferred oral contraceptives, reasons 
for this preference included the perception that oral 
contraceptives are safer (63%) and easier (42%) to 
use, do not cause amenorrhoea (19%), are more 
effective (9%), are reversible (9%), and allow women 
to control their own fertility confidentially (16%).
Factors influencing injectable 
contraceptive continuation
Multivariate analysis was conducted to explore 
factors, both socio-demographic and use-related, 
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influencing the continuation of injectable 
contraceptive use. Findings, presented in Table 3.11, 
compare women who discontinued use of injectable 
contraceptives after the first dose with those who 
continued for two or more doses (Column 2), those 
who discontinued use of injectable contraceptives 
after the first or second dose with those who 
continued for three or more doses (Column 3), 
and those who discontinued use of injectable 
contraceptives after one to three doses with those 
who continued for four or more doses (Column 4).
Findings suggest that continuation was associated 
with a number of socio-demographic and use-
related factors. As far as socio-demographic factors 
are concerned, for example, findings show that the 
odds that a woman had continued to use injectable 
contraceptives for at least six or nine months were 
unrelated with most socio-demographic variables. In 
contrast, the odds that a woman had continued to 
use injectable contraceptives for at least 12 months 
or four doses were greater among younger and better 
educated women, and those with larger numbers 
of children at the time of adopting injectable 
contraceptives as compared to other women.
Among use-related factors, the odds that a woman 
had continued to use injectable contraceptives 
for at least 6 months were greater among those 
who reported that the decision to use injectable 
contraceptives was made by both the woman and 
her husband, and were much lower among women 
who experienced menstrual disturbances only or 
both menstrual disturbances and other side effects 
compared to other women. Notably, continuation 
was not affected by the quality of care that is, 
whether or not the health care provider had 
answered all their questions satisfactorily. In contrast, 
the odds that a woman had continued to use 
injectable contraceptives for nine or more months 
were greater, as in the earlier case, among women 
who had reported joint decision-making and lower 
among those who experienced menstrual and other 
side effects; the odds were also greater among those 
who reported good quality of care as compared with 
other women. This general picture was evident also 
among women who had continued to use injectable 
contraceptives for 12 or more months compared 
to other women, except that joint decision-making 
was no longer significant in influencing method 
continuation.
Summary
Findings suggest that women obtained information 
about injectable contraception largely from health 
care providers, but also from family and friends. 
Irrespective of the source of information, about 
two-thirds of women who had adopted injectable 
contraception had made the decision to do so 
themselves, either on their own or together with 
their husband.
Injectable contraceptive related counselling was 
somewhat incomplete. While almost all the women 
had been informed about the need for three-monthly 
re-injections and their cost, and most had been 
informed about how the method works and the fact 
that it is a non-terminal method, fewer than half 
had been counselled about possible side effects, what 
to do if side effects were encountered, and the need 
to return to the service provider or facility in case of 
doubts about the method or if any side effects were 
experienced.
As other studies have observed, more than four in 
five women had experienced at least one side effect, 
largely menstrual disturbances or backache, weakness 
and weight gain. However, among women who had 
continued using injectable contraceptives for three or 
more doses, a comparison of side effects experienced 
by women between doses suggested that while the 
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experience of menstrual disturbances, and notably 
amenorrhoea, declined marginally between doses, 
heavy bleeding fell significantly between the first 
and second doses. Experience of other side effects, 
in contrast, and notably weight gain, increased 
in the period between the first and second doses, 
and levelled off thereafter, while the experience of 
weakness and back pain increased more modestly 
between the first and second doses, and also levelled 
off thereafter. In all, about three-fifths of all women 
who experienced a side effect had complained 
about it to a health care provider and about one 
half noted that the side effect had affected their 
ability to perform their household responsibilities. 
Indeed, women who had experienced three or more 
side effects were more likely than other women to 
so report; women who had experienced menstrual 
disturbances were, on average, less likely to have 
complained and less likely to have reported that the 
side effect had affected their ability to perform their 
household responsibilities than were those who had 
experienced other side effects.
Life table continuation rates suggest that many 
women discontinued using injectable contraceptives 
after the first injection, and by 12 months, just 23 
percent were continuing to use the method. Reasons 
for discontinuation centred largely around the side 
effects experienced, with two-thirds of all those who 
had discontinued injectable contraceptive use citing a 
health-related factor, largely menstrual disturbances, 
as the reason. Many fewer cited method-related 
reasons (that they planned to switch to another 
method, did not like the method, had doubts 
about it, needed a break from it, or that it was 
inconvenient to use), reasons related to difficulties in 
accessing supplies, and fertility-related reasons (that 
they wanted to become pregnant, were infecund or 
did not engage in sexual relations regularly). That 
side effects were a central reason for discontinuing 
injectable contraceptive use was evident from 
findings suggesting that life table continuation 
rates were considerably lower among women who 
experienced both menstrual disturbances and other 
side effects than among those who experienced just 
menstrual disturbances.
Following discontinuation of injectable 
contraceptive use, about three in ten women 
switched immediately to another contraceptive 
method; a similar proportion switched to another 
method (including those who switched back to 
injectable contraceptives) after a gap of one to three 
months, and about two in five women did not 
adopt another method even after a three month 
gap. All-method continuation rates suggest that 
by 12 months of the initial adoption of injectable 
contraceptives, as many as 45 percent continued to 
be protected by one or other contraceptive method. 
All-method continuation rates that include those 
who had discontinued contraception for a period of 
one to three months (but had not become pregnant) 
before switching to another method, suggest an 
all-method continuation rate of 53 percent at 12 
months.
Overall, women were divided about the 
acceptability of injectable contraceptives. As many as 
one quarter of all women could not identify a single 
positive feature, and a slightly larger proportion 
could not identify a single negative feature of 
injectable contraceptives. Key positive features 
included that it enables women to control their 
fertility, that it is long-acting and does not require 
a daily routine, that it is easy to use and that it is 
safe. Key negative features, as expected, were the 
menstrual disturbances and other health-related side 
effects caused by injectable contraceptives. Women 
who had discontinued the method before completing 
12 months of use (three doses or fewer) were more 
likely than those who had continued using the 
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method for 12 months or more (at least four doses) 
to report its negative features and correspondingly, 
were significantly more likely to report such positive 
features as its safety and effectiveness, its long-
acting nature and ease of use than were those who 
had discontinued before completing 12 months 
of use. Over one half of women who had used 
injectable contraceptives as well as the IUCD or oral 
contraceptive pills (prior to adoption of injectable 
contraceptives or post discontinuation) reported 
that they preferred to use injectable contraceptives. 
Leading reasons for this preference included its 
perceived safety, ease of use, long-acting nature and, 
in comparison to oral contraceptive pills, that it did 
not require a daily routine.
Continuation of injectable contraceptive use, 
as assessed by multivariate analysis, was largely 
associated with a number of socio-demographic and 
use-related factors. The odds that a woman had 
continued to use injectable contraceptives for at 
least 12 months, for example, were greater among 
younger and better educated women, and those with 
larger numbers of children at the time of taking the 
first dose of injectable contraceptives as compared 
to other women; the odds were greater among 
those who had received good quality of care and 
lower among those who had experienced menstrual 
disturbances along with other side effects. Some 
notable differences appeared to mark discontinuation 
earlier than 12 months. For example, joint decision-
making with the husband was an important correlate 
of continuation beyond three and six months but 
did not remain significant thereafter; and quality of 
care was unrelated with continuation beyond three 
months but became significant thereafter.
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A secondary objective of this study was to assess 
the extent to which new method adopters opted for 
injectable contraceptives and their motivations for 
adopting the method selected. A survey, comprising 
exit interviews, was conducted among women 
seeking to adopt a contraceptive method from the 
facilities from which our sample of women who 
had earlier adopted injectable contraceptives was 
drawn. Interviewers spent two to three days in each 
facility and interviewed all consenting women who 
sought to adopt contraceptive services on those days. 
The interviews aimed to explore two main issues: 
the extent to which pre-adoption counselling had 
included injectable contraceptives among the range 
of contraceptives described to the woman and the 
kind of information about injectable contraceptives 
provided; and the method finally adopted and 
reasons for adopting or not adopting injectable 
contraceptives. A total of 117 women seeking 
to adopt contraception in study facilities were 
interviewed.
Pre-adoption counselling
Descriptions of pre-adoption counselling suggest 
that injectable contraceptives were included among 
the basket of contraceptives offered to just one 
quarter (24%) of women seeking contraception, as 
seen in Table 4.1. Of the 28 women who reported 
that the health care provider had indeed discussed 
injectable contraceptives with them, the kinds of 
issues addressed resemble those described by women 
who had adopted injectable contraceptives in March 
to September, 2010. For example, all women were 
informed that they would have to return to the 
facility every three months to repeat the dose of 
injectable contraceptives and 82 percent were told 
the advantages of using the method. However, 
considerably fewer reported that the health care 
ChaPtEr 4
Perspectives on injectable contraceptives 
among women seeking to adopt contraception
table 4.1
Percentage of women seeking to adopt contraception by pre-adoption counselling received
Content of pre-adoption counselling
Women seeking to 
adopt contraception
Health care provider talked about injectable contraceptives 23.9 
(N=117)
Among those to whom the health care provider talked about injectable 
contraceptives N=28
Told about the advantages of using injectable contraceptives 82.1
Told about the three month follow-up visit for repeating injections 100.0
Told about the cost of each injection 57.1
Told about the possible side effects of injectable contraceptives 46.4
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provider had informed them about the cost of each 
dose of injectable contraceptives (57%), and fewer 
than half (46%) reported receiving information 
about the possible side effects of the method.
Method adopted
The large majority of women reported that they 
had decided the method they wished to adopt prior 
to attending the facility. As evident from Table 4.2, 
the majority (62%) had planned to adopt and had 
indeed adopted female sterilisation (60%). Others 
had opted for non-terminal methods: 15 percent 
for the IUCD, five percent for oral contraceptives 
and four percent for injectable contraceptives. In 
short, one-sixth of all women who had a specific 
non-terminal method in mind had planned to adopt 
injectable contraceptives and one-fifth (10 of 47) 
of those who adopted a non-terminal method had 
opted for injectable contraceptives. We acknowledge 
that this large proportion opting for injectable 
contraceptives may reflect the fact that the NGO 
facilities in which the study was located were well-
known for offering injectable contraceptives; and 
hence their clientele may not be representative of 
all women seeking to adopt contraception more 
generally. Aside from those who had a method in 
mind when they visited the facility, 11 percent 
reported that they had been undecided about which 
method to adopt when they visited the facility.
Most women, 95 of the 104 who had a 
particular method in mind (91%), had adopted 
the method they had intended to adopt. Of the 13 
women who were undecided about which method 
to adopt, two opted for tubal ligation, seven for 
oral contraceptives, two for condoms, and two for 
injectable contraceptives. Of the eight women who 
had planned to adopt a particular method and 
adopted a different method, five, two and one, 
respectively, had intended to adopt tubal ligation, 
the IUCD and oral contraceptive pills, but none of 
table 4.2
Percentage of women seeking to adopt contraception by contraceptive method they intended to 
adopt and the method adopted
Method 
All women
Method the woman 
intended to adopt
Method adopted by 
the woman
Male sterilisation 0.9 0.9
Female sterilisation 62.4 59.8
Iintrauterine contraceptive device 14.5 12.8*
Oral contraceptive pills 5.1 14.5
Condom 1.7 3.4
Injectable contraceptives 4.3 8.5
No method planned 11.1 **
Number of women 117 117
Note: *Includes one woman who was provided the emergency contraceptive pill and asked to return in two weeks to have the 
IUCD inserted; **Includes 13 women who adopted tubal ligation(2), oral contraceptive pills(7), condoms(2) and injectable 
contraceptives(2).
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these women obtained the method she had originally 
decided upon; instead, the methods adopted were 
oral contraceptives (five women) and injectable 
contraceptives (three women). Most women who had 
not adopted their intended method reported that 
the health care provider had dissuaded them from 
adopting that method, indicating that it would not 
be appropriate in their situation (further details were 
not probed).
In short, a comparison of the method women 
intended to adopt and the method actually adopted 
suggests a shift away from terminal to non-terminal 
methods, and towards such non-terminal methods as 
oral and injectable contraceptives.
Decision-making with regard to the method 
finally adopted suggests that 80 percent of all 
women had made the final decision about which 
method to adopt on their own or together with their 
husband, mother-in-law or health care provider. As 
many as 62 percent reported that they and their 
husbands, they alone (18%) and their husband alone 
(13%) had made the final decision. Some 21 percent 
reported the involvement of a health care provider 
and nine percent of their mother-in-law. It is notable 
that one-fifth of all women were excluded from the 
final decision on which method to adopt (not shown 
in table).
Method preferences
Exit interviews explored the reasons that the 107 
women who had adopted methods aside from 
injectable contraceptives gave for not adopting this 
method. As shown in Table 4.3, the large majority—
as many as two-thirds—reported lack of awareness 
of injectable contraceptives. A second leading 
factor dissuading women from adopting injectable 
contraceptives was the fear of side effects (18%). 
Other concerns included difficulty in accessing the 
facility for repeat doses (9%), high cost of repeat 
table 4.3
Reasons for non-adoption of injectable contraceptives
Reasons given for non-adoption of 
injectable contraceptives 
Women who adopted 
all methods other 
than injectable 
contraceptives 
(%)
Number of women 
who adopted 
the IUCD  
(n)
Number of women 
who adopted oral 
contraceptives 
(n)
Not aware of injectable 
contraceptives 65.4 8 8
Fear of side effects of injectable 
contraceptives 17.8 4 3
Difficulty in accessing the facility for 
repeat doses 9.3 2 2
Husband disapproves of injectable 
contraceptives 7.5 1 1
Cost of repeat doses 2.8 0 1
Preference for tubal ligation 0.9 0 0
Health care provider dissuaded 
injectable contraceptive use 3.7 1 2
Number of women 107 14 17
Note: Multiple responses possible.
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doses (3%), husband’s disapproval of the method 
(8%) and preference for tubal ligation (1%). In 
addition, four percent of women reported that 
the health care provider had dissuaded them from 
adopting injectable contraceptives.
A roughly similar picture emerges when we 
explore the reasons that women who adopted the 
IUCD and oral contraceptives gave for preferring 
these methods to injectable contraceptives. While 
numbers are small, it is clear that the potential side 
effects of injectable contraceptives are a significant 
deterrent. So too were difficulties associated with 
accessing the facility for repeat doses of injectable 
contraceptives, even compared to oral contraceptives 
which could be accessed from a number of outlets 
closer to the woman’s home and did not require a 
return visit to the facility.
Women who had adopted injectable contraceptives 
highlighted a number of advantages of the method 
over oral contraceptive pills, for example. Of the 10 
women who had adopted injectable contraceptives, 
five reported that a key advantage over oral 
contraceptives was that it is long-acting and does not 
require a daily routine; five also reported that it is 
“easier” to use; three reported that it offered women 
greater confidentiality; and two mentioned that it 
is a highly effective method. Not a single woman 
reported that the method had fewer side effects (not 
shown in table).
Summary
Exit interviews with women seeking to adopt 
contraception revealed that just nine percent of 
women seeking contraception and about one-fifth 
of those who opted for a non-terminal method at 
study facilities had adopted injectable contraceptives. 
Findings suggest a number of factors underlying 
the relatively limited adoption of this method. 
Many women were unaware of the method. 
Indeed, two-thirds of those who had adopted other 
methods reported that they were unaware of the 
availability of injectable contraceptives. As most 
women had adopted the method they had intended 
to adopt prior to visiting the facility on the day 
of the interview, this lack of general awareness is 
likely a key factor inhibiting the use of injectable 
contraceptives. At the same time, information was 
unlikely to be provided at the facility: few women, 
just one in four, were informed about the availability 
of injectable contraceptives during pre-adoption 
counselling by the health care provider.
Further insights come from women who 
had adopted methods other than injectable 
contraceptives. For example, fear of side effects 
was clearly a major factor inhibiting the adoption 
of injectable contraceptives. The cost of injectable 
contraceptive repeat doses was an inhibiting factor 
for a few women who adopted oral contraceptive 
pills and the IUCD. Moreover, the need to 
access the facility for repeat doses of injectable 
contraceptives was perceived as a serious disadvantage 
by many who regarded the IUCD, in comparision, 
as a method not requiring repeated follow-up and 
oral contraceptives, as one that could be purchased 
or obtained from facilities and outlets closer to 
home.
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ChaPtEr 5
Perspectives of health care providers on 
injectable contraceptives
The study also sought to obtain the perspectives of 
health care providers on a number of issues relating 
to the use of injectable contraceptives. Interviews 
addressed, for example, health care providers’ own 
experience of providing injectable contraceptives: 
the number of clients to whom they had supplied 
injectable contraceptives, the type of counselling 
provided to users and potential users, and provider 
biases, if any, in terms of which type of client 
should be offered or should be denied injectable 
contraceptives. They were also probed about the 
experiences of their clients who had used injectable 
contraceptives, and specifically, their clients’ prior 
awareness about the method, continuation, side 
effects experienced, follow-up and acceptability. 
Finally, they were asked for their opinion about the 
possible inclusion of injectable contraceptives in the 
national programme, and their recommendations, if 
any, about how the method should be rolled out.
As mentioned earlier, a total of 16 health care 
providers were interviewed, at least one from 
each participating NGO. All health care providers 
indicated that the facility in which they worked 
offered a range of contraceptive services, including 
both terminal methods and injectable contraceptives, 
and abortion services. A few also mentioned the 
provision of antenatal and postpartum services, 
services related to sexually transmitted infections and 
adolescent counselling.
Health care provider perceptions about 
method preferences of clients
Health care providers were asked to estimate the 
number of women to whom they had provided 
injectable contraceptives in the year and month 
preceding the interview. A range of responses were 
received, for example, from ‘20–40’ to ‘about 1000’ 
in the year preceding the interview, and from ‘2–3’ 
to ‘20–30’ in the month preceding it. A few health 
care providers stated that large numbers of women 
sought tubal ligation:
Very few come for other contraceptives; the 
maximum number of clients come for sterilisation 
as it is a permanent method. They don’t have 
much interest in temporary methods as they have 
many things (doubts) in their mind regarding the 
side effects of these methods. (Dr. B, age 
group 40–49)
Most women accept sterilisation. (Dr. D, age 
group 30–39)
Rural clients prefer a permanent method. Urban 
clients accept temporary methods; they use 
injectables and the Cu-T (IUCD) as temporary 
methods. (Dr. K, age group 40–49)
Other health care providers discussed the demand 
for non-terminal methods among women seeking 
contraception. Four health care providers said 
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that the IUCD (Cu-T) was the most commonly 
desired non-terminal method among women seeking 
contraception in their facilities. Health care providers 
indicated:
Few clients use oral contraceptive pills. Mostly, 
they use the Cu-T as a temporary method. 
(Dr. J, age group 50+)
Mostly, women accept IUCDs. (Dr. C, age 
group 50+)
(Most women opt for the) Cu-T. (Dr. A, age 
group 50+)
Aside from sterilisation, most women accept the 
Cu-T. (Dr. M, age group 40–49)
However, several health care providers noted 
women’s interest in injectable contraceptives:
They use two methods, the Cu-T first, and 
next, they prefer injectables. (Dr. H, age 
group 30–39)
Mostly, women accept oral contraceptives; there 
are some misconceptions about the Cu-T... 
Nowadays, many women have been showing a 
preference for injectables. (Dr. N, age 
group 40–49)
Some women (are interested); (because) injectable 
contraceptives have few side effects; pills give 
problems like nausea, vomiting etc. On the other 
hand, if the husband doesn’t wish to use Nirodh 
(condom) or doesn’t use it properly, there are 
chances of the woman conceiving. Women feel 
assured that with injectable contraceptives, they 
will not conceive and that it has few side effects; 
also, after proper counselling, their misconceptions, 
such as concerns about weakness, are reduced. 
(Dr. N, age group 40–49)
Women like to accept injectable contraceptives as 
the method is easy to use; in comparison, they 
don’t like to accept the Cu-T because of the fear 
of infection and the insertion procedure. 
(Dr. P, age group 50+)
Health care provider perceptions about 
the advantages and disadvantages of 
injectable contraceptives
Health care providers were mixed about their views 
on the appropriateness of injectable contraceptives as 
a viable method for their clientele. Almost all agreed 
that it is a safe and effective method,:
The first advantage (of injectable contraceptives) 
is their low failure rate; second, the method is 
good as there is no problem of taking it daily 
as in the case of pills, and third, privacy can be 
maintained. (Dr. G, age group 50+)
It is a good method but there are side effects. 
(Dr. A, age group 50+)
Injectable contraceptives are a very good, effective 
and safe method, provided proper counselling is 
given regarding side effects...it is not required 
to be taken daily. Secondly, after a gap of three 
months, it is not absolutely necessary to take the 
next dose on a fixed date as its window period is 
also good. (Dr. L, age group 50+)
Injectable contraceptives are a confidential method; 
privacy is maintained and it has to be taken only 
once in three months. (Dr. P, age group 50+)
As a temporary method for one or two years, it 
is a good method. However, if it is to be used 
for a longer period, it is important to know its 
advantages and disadvantages. (Dr. K, age 
group 40–49)
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We prefer the Cu-T because if there is any 
problem or it doesn’t suit the woman, we 
can remove it immediately, but if injectable 
contraceptives enter the body, we cannot do 
anything. Also, after discontinuing injectable 
contraceptives, the woman’s menses doesn’t return 
for six months to a year. (Dr. M, age 
group 40–49)
At the same time, health care providers 
acknowledged that the method is associated with 
many side effects and that these side effects made 
injectable contraceptives an unattractive option for 
women. In fact, every single health care provider 
noted that menstrual disturbances are a major side 
effect of injectable contraceptives. Indeed, several 
said that neither heavy bleeding nor amenorrhoea 
were acceptable side effects for women. Health care 
providers reported that many women who experience 
these side effects express the fear of having a serious 
disease and those who experience amenorrhoea 
fear that they are pregnant. Moreover, because of 
cultural practices that forbid menstruating women 
from entering the kitchen or praying, heavy bleeding 
or irregular menstruation affected their ability to 
perform these regular tasks:
It is a good method, but there are side effects.... 
When it suits the woman, she is happy and takes 
three to four doses. But then, if a problem occurs, 
she asks me, ‘What kind of injection have you 
given me?’ (Dr. A, age group 50+)
Not a very good method; it disturbs menstruation 
greatly. Women come here in tension as they 
have continuous bleeding or bleeding (menstrual 
period) has completely stopped. (Dr. B, age 
group 40–49)
It is a good method but it has many side effects 
like amenorrhoea. In such a situation, the client 
gets disturbed, thinking about why she does not 
menstruate; she is afraid that she may be suffering 
from some disease. (Dr. C, age group 50+)
Side effects are not acceptable; women feel 
disturbed if they experience amenorrhoea and 
worry whether or not they are pregnant again. 
(Dr. E, age group 30–39)
Women who have bleeding-related problems, feel 
uneasy; otherwise, they are happy. Fifty percent 
discontinue the method because of amenorrhoea. 
(Dr. G, age group 50+)
I don’t find any drawback as such, but if 
amenorrhoea occurs as a side effect, then it is a 
cause for concern. (Dr. N, age group 40–49)
Irregular bleeding is a very big problem with 
injectables. It is a problem in our context because 
when a woman is bleeding, she is unable to 
worship God and it disturbs her psychologically; 
so, women don’t wish to accept the method. The 
second problem is that if a woman experiences 
irregular bleeding, we are unable to tell her when 
it will stop. Once injectables are used, the effect 
of the drug remains for three months, and we 
can’t do anything about it. (Dr. O, age 
group 40–49)
A number of health care providers also stated that 
delayed resumption of menstruation and prolonged 
time to conception following discontinuation of 
injectable contraceptives was a disadvantage especially 
for women intending to have another pregnancy 
on discontinuation of the method. They argued 
that time to conception was far longer than that 
associated with the Cu-T or oral contraceptives, and 
may not therefore be attractive to women seeking to 
space their births. For example:
After removing the Cu-T, the woman can 
conceive easily whereas it takes some time to 
conceive after stopping injectables.... Women know 
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that after stopping injectables, it will take one 
year to conceive, so they stop after a few doses. 
(Dr. H, age group 30–39)
Some women are not able to conceive for many 
days after they stop using injectable contraceptives. 
(Dr. F, age group 40–49)
Sometimes, after stopping the injections, there 
is a delay in (the resumption of ) menses for six 
months or a year. (Dr. A, age group 50+)
After stopping (discontinuing use), women 
are unable to conceive; they go into secondary 
infertility and have to undergo treatment for 
many days (for the resumption of menstruation). 
(Dr. B, age group 40–49)
After discontinuing injectable contraceptives, the 
next pregnancy could be delayed; it is not so with 
other methods. The calcium level also goes down 
with the use of this method; this is not visible 
but it could cause a problem. (Dr. K, age 
group 40–49)
If a client is newly married and does not have 
even one child, we cannot give her injectables 
because sometimes fertility is delayed, whereas 
after discontinuing the oral contraceptive pill, 
pregnancy can happen soon. (Dr. L, age 
group 50+)
Finally, we note that although injectable 
contraceptives are recommended for use in the 
postpartum period and by lactating women (World 
Health Organization, 2010), this advantage was not 
specifically indicated by a single health care provider.
Health care provider perceptions 
about factors dissuading women from 
adopting injectable contraceptives
Several health care providers also highlighted the 
obstacles that dissuaded women from adopting 
injectable contraceptives, once fully informed. 
Leading obstacles included the inconvenience of 
returning to the facility every three months for re-
injections, fear of side effects and cost. For example:
Everyone asks about injectables, but they want a 
one-time injection: if we tell them that they will 
have to come every three months, they are not 
willing (to adopt the method). (Dr. C, age 
group 50+)
They don’t have much interest (in injectable 
contraceptives) as they have many doubts in 
their mind about side effects. (Dr. B, age 
group 40–49)
Mostly women prefer the Cu-T because once 
inserted, they can be tension—free; they just have 
to pay Rs 50 once, whereas for injectables they 
have to pay Rs 50 every three months. 
(Dr. F, age group 40–49)
Health care provider perceptions on 
the appropriateness of injectable 
contraceptives for different groups of 
women
In the course of the in-depth interview, we made 
efforts to gauge the perspectives of health care 
providers about the appropriateness of injectable 
contraceptives for women in India, including 
whether health care providers would hesitate to offer 
injectable contraceptives to poor or poorly educated 
women.
While almost all health care providers were in 
agreement that injectable contraceptives are a safe 
and effective method, many acknowledged that it 
is not an appropriate method for all women. For 
example, several health care providers indicated that 
they would recommend the method to only certain 
categories of women based on the woman’s age and 
fertility intentions; for example, they would offer 
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it to women who do not want another child, or to 
older women, but would refrain from suggesting it to 
those who are newly married or to those who intend 
to have a child on discontinuation of the method.
If the woman is young or newly married, I don’t 
recommend the Cu-T generally, but condoms 
or oral pills are fine. On the other hand, if the 
woman is older and her family is complete, we 
advise sterilisation. (Dr. E, age group 30–39)
If the client is newly married then we don’t 
recommend the Cu-T or injectable contraceptives 
as there are chances of infection with both these 
methods, and if infection does occur, the entire 
blame is placed either on the provider or on the 
method. (Dr. P, age group 50+)
If the client doesn’t even have one child, I do not 
advise injectables. (Dr. J, age group 50+)
We mostly recommend the Cu-T and injectables, 
but we prefer the Cu-T for women who may 
want another child. (Dr. H, age group 30–39)
It is a good method, provided the woman’s family 
is complete and she is above 35 years. (Dr. I, age 
group 30–39)
Age matters because at pre-menopausal ages, 
hormonal methods of contraception should be 
avoided. (Dr. O, age group 40–49)
A few health care providers described in detail 
the extent to which it was important to obtain the 
woman’s full history as there were certain health 
conditions under which they would not recommend 
injectable contraceptives. For example:
Normally we do not advise injectables to a 
woman who has a bleeding-related problem, a 
cyst in the ovaries, a problem in the cervix or a 
cyst in the breast. So, we avoid giving injectables 
to such women. (Dr. G, age group 50+)
We have to assess her family background, 
her history, and do her physical screening. A 
particular method may not be suitable for 
certain clients, and even so, not for her entire 
reproductive life. If a woman comes after delivery, 
we prescribe the oral pill. We also need to see the 
age of her last child and which method she wishes 
to adopt. (Dr. L, age group 50+)
As regards offering injectable contraceptives 
to poor or poorly educated women, health care 
providers expressed divers views. A number of 
health care providers maintained that the extent to 
which the client was educated did not affect their 
decision to offer injectable contraceptives to them. 
For example, eight health care providers argued that 
socioeconomic factors were unimportant:
Her age, education or socioeconomic condition are 
not significant. (Dr. B, age group 40–49)
The client’s socioeconomic condition is not 
significant. (Dr. D, age group 30–39)
The woman’s socioeconomic condition is not 
significant. (Dr. G, age group 50+)
Education is not significant; if everything is 
explained nicely, even illiterate women are able to 
understand everything. (Dr. F, age group 40–49)
We provide information about each method, so 
education doesn’t matter much—but it matters for 
natural methods like the safe period etc. 
(Dr. H, age group 30–39)
Economic condition is not important; woman of 
all classes accept it (injectable contraceptives). 
(Dr. I, age group 30–39)
Women, who are less educated or belong to 
a lower income group, accept it (injectable 
contraceptives); they have more faith in the 
doctor. (Dr. L, age group 50+)
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Economic conditions and educational 
qualifications are of no significance as most clients 
coming from rural areas are illiterate or have 
studied up to a maximum of 6th class only. 
(Dr. M, age group 40–49)
At the same time, eight other health care health 
care providers affirmed that the poorly educated 
were less likely to comprehend the requirement of 
three-monthly injections and side effects associated 
with injectable contraceptives. Four of these health 
care providers suggested that they needed to spend 
more time explaining the method to poor or poorly 
educated women than others. For example:
If a woman is educated, she is able to understand 
(what she is told) about injectable contraceptives; 
we need to explain at length to village women. 
(Dr. A, age group 50+)
We can explain everything regarding injectable 
contraceptives and other methods properly to 
educated women and they understand it. As 
compared to poorly educated women, educated 
women understand injectable contraception better. 
(Dr. C, age group 50+)
Educational qualifications matter because we have 
to explain more to a lesser educated client as only 
by doing so, we can follow up that client, which 
is very important. (Dr. O, age group 40–49)
Yes, educational qualification is significant...
educated women understand the method and 
easily follow instructions about how to use the 
method. (Dr. P, age group 50+)
The remaining four health care providers of this 
group maintained that they would prefer to provide 
methods other than injectable contraceptives to poor 
or poorly educated women. Two reported that they 
would recommend injectable contraceptives to poorly 
educated women, but that the economic condition 
of the household did play a role in their decision to 
offer the method to the woman. For example:
Educational qualification is not significant... but 
socioeconomic condition matters because for some 
methods, the charges are too high and poor clients 
prefer to accept the cheapest method. (Dr. K, age 
group 40–49)
Economic status is important to some extent 
because if a woman needs to get a test done from 
a private facility, and her economic condition 
is not good, she will not be able to get her test 
done so easily. Injectables are not available in 
government facilities either, so we can give the 
method to the client only if she can afford it. 
(Dr. N, age group 40–49)
Two others reported that they would recommend 
other methods to a poorly educated woman. For 
example:
Education is significant as educated women 
understand easily. They also understand the 
importance of follow up; to less educated women, 
we suggest the use of condoms. (Dr. E, age 
group 30–39)
Yes, educational qualification is significant…. I 
recommend methods to women according to their 
needs and educational status. (Dr. J, age 
group 50+)
Injectable contraceptive related 
counselling offered by health care 
providers
Efforts were made to understand the kind of 
counselling that health care providers offered 
potential clients and specifically, whether they 
involved the husband in the counselling session and 
if they permitted clients to make the final decision 
to adopt the method on her own.
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For the most part, health care providers indicated 
that counselling entailed the provision of such 
information as the mechanics of the method (how 
often it must be taken) and the kind of side effects 
that may occur. All health care providers indicated 
that they informed women about such side effects 
as amenorrhoea and heavy bleeding, and that the 
woman should return to the clinic if she experiences 
these side effects. However, although several health 
care providers had also discussed weight gain as 
a disadvantage, not a single health care provider 
mentioned that they would inform the client about 
this side effect.
We tell them after how many days it (the 
injection) is to be taken, about complications; we 
tell them everything. (Dr. A, age group 50+)
We inform them that this injection will function 
for three months only. We tell them about its side 
effects etc. (Dr. C, age group 50+)
We tell them that the monthly period may stop, 
bleeding may occur between periods, but there 
is nothing to worry about. (Dr. D, age 
group 30–39)
We provide information regarding side effects like 
bleeding, stopping of menses (amenorrhoea) and, 
at the same time, we also counsel them that there 
is nothing to worry about. (Dr. M, age 
group 40–49)
Several health care providers narrated, in detail, 
the importance of gathering the woman’s complete 
history; they also highlighted to their clients 
the mechanics of the method and the potential 
menstrual disturbances that could arise. For example:
We counsel all women about injectable 
contraceptives but normally we do not advise 
injectables to a woman who has a bleeding-
related problem, a cyst in the ovaries, a problem 
in the cervix or a cyst in the breast. So, we 
avoid giving injectables to such women. First, I 
tell them that injectables are also a method of 
contraception which is to be taken after every 
three months and by taking which, the woman 
will not conceive. The second thing is that some 
women have a misconception that the injection is 
effective for three or five years; so, we clarify this 
too. Moreover, we also provide them information 
about irregular bleeding and amenorrhoea as side 
effects of the method; due to this, although some 
women refuse to take injectables, most accept the 
method. (Dr. G, age group 50+)
I take information about her menstrual history, 
menstruation-related problems and, at the same 
time, information about whether or not she has 
used any method previously and, if so, which 
method she has used and whether she had any 
problems using that method. If the woman is 
young or newly married, I don’t recommend the 
Cu-T generally, but condoms or oral pills are 
fine. On the other hand, if the woman is older 
and her family is complete, we advise sterilisation. 
I tell them about the side effects of the injection 
such as amenorrhoea. If the woman is lactating, 
I tell her that her milk may be reduced. At the 
same time, I advise her to take an injectable 
dose after every three months. I also advise her to 
come to the clinic in case of any side effect and 
assure her that there is nothing to worry and the 
side effects, if any, can be cured with medicines. 
(Dr. E, age group 30–39)
We need to know the client’s complete history: 
whether she has any infection or any other 
problem. Most of our clients don’t have such 
problems; hence, we don’t discuss all these things 
with all our clients... First of all, I provide 
information regarding doses—that the injection is 
given after every three months, and by doing so, 
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a child is not conceived, and that mostly, there is 
no problem (with its use). But it is important to 
also tell them about one side effect of injectable 
contraceptives and that is, secondary amenorrhoea. 
If we don’t provide information about this side 
effect to the client, she will blame us if she 
happens to suffer from it later. (Dr. H, age 
group 30–39)
We have to assess her family background, 
her history, and do her physical screening. A 
particular method may not be suitable for 
certain clients, and even so, not for her entire 
reproductive life. If a woman comes after delivery, 
we prescribe the oral pill. We also need to see the 
age of her last child and which method she wishes 
to adopt. (Dr. L, age group 50+)
Several health care providers discussed the 
importance of including the husband in the 
counselling session, although at least in one case, 
the health care provider maintained that even when 
husbands attended the counselling session, they rarely 
participated or asked questions during the discussion. 
Other health care providers highlighted the link 
between the husband’s involvement and the quality 
of subsequent method use, and the perception that 
many women would not adopt a method without 
having discussed it with their husband. For example:
If both husband and wife are involved then 
acceptance is good; especially women who are 
educated want to take a decision after discussing 
with their husband. (Dr. K, age group 40–49)
Clients who belong to urban areas, generally come 
with their husband and he wishes to know which 
method is good for them, what are the advantages 
and disadvantages of the method, when to return 
and what they can do or not do. In particular, 
clients who are educated and whose husband is 
also educated, wish to have full information, but 
the husbands of clients who come from villages, 
don’t get involved. (Dr. M, age group 40–49)
It is important to involve the husband because it 
is the decision of both the husband and the wife. 
If a woman accepts a method on her own, and 
if her husband or other family members, like her 
mother-in-law or sister-in–law, tell her that she 
will have to face many problems by using the 
method, she will not be able to continue its use 
and will drop the method. Subsequently, even if 
she doesn’t wish to, she may become pregnant. So, 
by involving the husband, the use (continuation) 
of the method will improve. (Dr. N, age 
group 40–49)
Some health care providers indicated that they 
specifically requested the husband to attend the 
counselling session if the woman permitted. For 
example:
Yes. I call both; I call the husband specially. 
(Dr. I, age group 30–39)
During counselling, we also involve the husband 
because both should know what is happening. 
(Dr. G, age group 50+)
A few health care providers remarked that 
husbands were more likely to comprehend 
instructions than were women or that the husband’s 
consent was required, and hence it was important 
that the husband also attended the counselling 
session. For example:
If the woman does not understand (the 
instructions), we tell her to call her husband and 
explain them to him; later, we do whatever they 
desire. (Dr. A, age group 50+)
The husband should be involved because the 
consent of both is required. (Dr. H, age 
group 30–39)
45
Chapter 5: Perspectives of health care providers on injectable contraceptives
Health care providers were fairly unanimous in 
their perception that the final decision on which 
method to adopt was taken by the client, either on 
her own, or together with her husband.
Health care provider perceptions 
about follow-up, discontinuation and 
switching
Health care providers were mixed in their 
perceptions about the duration of use of injectable 
contraceptives, with a few noting that their clients 
tended to use the method for over a year and others 
noting that women rarely continued beyond two 
doses. There was more consistency across health 
care providers in terms of the factors underlying 
discontinuation, with almost all health care providers 
noting that the experience of side effects, specifically 
menstrual disturbances, was a leading reason for 
method discontinuation. For example:
Ninety percent of clients come on time and, on 
average, take four to five doses. (Dr. J, age 
group 50+)
Women are happy with this method and they 
come regularly for the next dose. (Dr. P, age 
group 50+)
Most clients take seven to eight doses and then 
discontinue. (Dr. K, age group 40–49)
In some exceptional cases, women may take 
injectables for four to five years, but mostly, 
women take four to eight doses only. (Dr. N, age 
group 40–49)
Mostly, women are irregular. After taking the 
first, second or third dose, they won’t come back 
for additional doses. (Dr. C, age group 50+)
If menses stops, they think they have conceived 
and discontinue the method (Dr. A, age 
group 50+)
Mostly, women take one or two doses, then 
discontinue. They think that irregular menses will 
affect their health and so they discontinue the 
injection. (Dr. C, age group 50+)
Because people have this thing in their mind that 
menstrual blood is dirty blood and if it stays 
inside the body, it will harm the body. This is 
why most women discontinue using injectable 
contraceptives. (Dr. G, age group 50+)
They take around seven to eight doses, then they 
don’t come; they drop the method because of side 
effects. (Dr. D, age group 30–39)
Half of all women discontinue it (injectable 
contraceptives) because of the problem of 
amenorrhoea. (Dr. G, age group 50+)
Women stop taking injectables because of the fear 
that if they don’t get their periods, other problems 
will occur. They tell me that their family 
members say that it is necessary that menses 
should happen and bleeding should occur. 
(Dr. O, age group 40–49)
In a few cases, weight gain was also mentioned 
as a reason for discontinuation. Some health 
care providers said that women discontinued the 
method prematurely because they wished to become 
pregnant, associating the method with delayed return 
to fertility. For example:
After three to four doses, they stop coming because 
of the side effect of weight gain. (Dr. E, age 
group 30–39)
Women know that after stopping injectables, it 
will take one year to conceive. So, they stop after 
four to five doses. (Dr. H, age group 30–39)
Finally, some health care providers stated that the 
inconvenience of having to visit the facility every 
three months dissuaded women from continuing 
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injectable contraceptive use. In contrast, the Cu-T 
was seen as a more convenient one-time solution, 
and oral contraceptives were more easily accessible. 
For example:
One problem is coming every three months 
(for the injection). In some homes, there is not 
much care for women and there is no one to 
accompany them; so, they discontinue. (Dr. B, 
age group 40–49)
Health care providers were also asked about 
whether women who discontinued injectable 
contraceptive use adopted other methods, and the 
preferred method to which they advised women to 
switch. Three methods were typically suggested—
tubal ligation, the IUCD and, to a lesser extent, oral 
contraceptives. Each method was perceived to have 
particular advantages: tubal ligation for those who 
had attained their family size, the IUCD for those 
who preferred a one-time method with no need 
for follow up, and oral contraceptives for women 
for whom regular menstruation was important. For 
example:
Women with two to three children get their 
sterilisation done. (Dr. K, age group 40–49)
After discontinuing injections, they prefer the 
IUCD and not (oral contraceptive) pills as 
they are afraid they will forget to take the pill 
regularly. (Dr. C, age group 50+)
Pills, so that menses is regular. (Dr. F, age 
group 40–49)
After (discontinuing) injectables, they prefer 
multiload (Cu-T). Women prefer the Cu-T 
because it can be removed at any time in case of 
any problem. (Dr. G, age group 50+)
Women who discontinue using injectables, get 
their tubectomy done if they don’t want more 
children, (Dr. L, age group 50+)
Health care provider perceptions 
about the inclusion of injectable 
contraceptives in the national 
programme
Almost all health care providers who discussed their 
views about the inclusion of injectable contraceptives 
in the national programme were positive about 
the inclusion of the method. Several health care 
providers perceived that the inclusion of injectable 
contraceptives in the programme would enhance the 
basket of methods available to women and thereby 
offer them greater choice:
(Injectable contraceptives) should be included in 
the government sector programme, as one more 
method will be added for women. (Dr. B, age 
group 40–49)
Yes. It is a good method and should be included. 
By doing so, one more methods will be available 
for women; it will be easily available to them. 
(Dr. H, age group 30–39)
Yes. It is a very good method. According to me, 
it should also be included in the government 
programme. If it is introduced in the government 
programme, it will be a fortunate thing for 
women because at this centre, I have seen that 
within two months of delivery, the woman 
conceives again. Even after delivering in a 
hospital, she doesn’t use any contraceptive 
because no one informs her about anything 
(contraception). (Dr. J, age group 50+)
This method should be available in villages the 
way it is available in cities...there is a shortage of 
this method in rural areas; it should be available to 
women at their doorstep. (Dr. L, age group 50+)
Yes. It is a good method...if it becomes available, 
women will get one more choice, and a method 
with few side effects. (Dr. N, age group 40–49)
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Yes. It is a very good method. The failure rate 
is very low and there is no need for surgery. 
Therefore, it is a better method than sterilisation. 
(Dr. P, age group 50+)
Others argued that its inclusion in the programme 
would be advantageous, but must be accompanied 
by good counselling and follow-up. For example:
It is a good contraceptive method and should be 
included (in the government programme), but 
counselling and awareness about the method is 
required. (Dr. B, age group 40–49)
Yes. It is a good method and should be included 
(in the government programme), provided there 
is proper follow up, because there is no use in 
taking just one dose for three months. 
(Dr. C, age group 50+)
Wherever these (contraception) facilities are 
provided, injectable contraceptives should be 
included. However, service providers should be 
fully trained and the other staff should also have 
information regarding injectables, how they act 
in the body and so on, because if counselling 
is good, the method will be accepted effectively. 
At many private places, clients are just given 
injectable contraceptives and don’t receive full 
information regarding the method. Therefore, 
they come to us later with complaints—because 
they have half (inadequate) information and lack 
of awareness about the method, no knowledge 
of contraception.... If we provide correct and 
complete information to women who are less 
educated, its acceptance will increase. (Dr. K, age 
group 40–49)
Yes, provided that (it is introduced) after doing 
a complete study of the side effects of injectable 
contraceptives. It will be good if it is subsequently 
brought into the government programme. (Dr. I, 
age group 30–39)
The side effects of injectables remain for such 
a long time that we are not sure about the 
method... a lot of research is needed before 
including it in the government programme. 
(Dr. O, age group 40–49)
Several health care providers agreed that injectable 
contraceptives were an effective and safe method, but 
believed that their side effects deterred women from 
adopting the method. For example:
Injectables are a good method but they can 
be used only for a short period, for keeping 
a gap of a maximum of three years. But for 
longer durations, it is not so—for example, if a 
woman is 30 years old and she wants lifetime 
service, (contraceptive protection throughout her 
reproductive years), it will not be appropriate 
to give her injectable contraceptives for 15 years 
because other problems could arise. (Dr. K, age 
group 40–49)
Regarding injectable contraceptives, I would just 
like to say that it is a very good method but 
it is accompanied by the problem of secondary 
amenorrhoea. (Dr. J, age group 50+)
Summary
In-depth interviews with health care providers 
corroborated many of the issues raised by women 
who had used injectable contraceptives and those 
seeking to adopt a contraceptive method. Most 
health care providers noted that a number of their 
clients had adopted injectable contraceptives and 
that interest in the method was frequently expressed. 
However, they were mixed about their views on 
the appropriateness of injectable contraceptives 
as a viable method for their clientele. Almost all 
agreed that it is a safe and effective method, but 
expressed concerns about the side effects of the 
method. Several health care providers indicated 
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that they would recommend the method to only 
certain categories of women, for example, those 
who do not want another child, or are older. Many 
noted that menstrual disturbances made injectable 
contraceptives an unattractive option for women, 
arguing that neither heavy bleeding nor amenorrhoea 
were acceptable side effects for women. A number of 
health care providers also mentioned that injectable 
contraceptives were not an appropriate non-terminal 
method for women intending to have another 
pregnancy on discontinuation of the method, 
that time to conception was far longer than that 
associated with the Cu-T or oral contraceptives. 
It is notable that not a single health care provider 
specifically reported recommending injectable 
contraceptives to recently delivered or lactating 
women, although the method is recommended for 
such women.
Health care providers expressed different views 
about offering injectable contraceptives to poor or 
poorly educated women. Most health care providers 
maintained that the educational attainment status 
of their clients did not affect their decision to offer 
injectable contraceptives to them. Some, however, 
perceived that the poor and the poorly educated 
found it more difficult than others to comprehend 
how the method works, and still others feared that 
the poor would not be able to bear the cost of re-
injections. This perception did not, however, deter 
most of these health care providers from offering 
the method to poorly educated and poor women; 
indeed, they reported that they spent more time 
explaining it to them than to others, and even 
recommended that the method be made more widely 
available to rural women through the programme.
For the most part, health care providers indicated 
that counselling entailed the provision of such 
information as the mechanics of the method (how 
often it must be taken) and the kind of side effects 
that may occur. All health care providers indicated 
that they informed women about such side effects 
as amenorrhoea and heavy bleeding, and that they 
should return to the clinic if they experienced these. 
Other side effects were mentioned less frequently 
(weight gain, for example). Several health care 
providers discussed the importance of including the 
husband in the counselling session, highlighting 
the link between the husband’s involvement and 
the quality of subsequent method use, and the 
perception that many women would not adopt 
a method without having discussed it with their 
husband. All health care providers emphasised that 
the final decision on method use was made by the 
woman herself, alone or together with her husband.
Health care providers held different views about 
the average duration of injectable contraceptive 
use among their clients, some suggesting that 
women discontinued after the first or second 
injection and others suggesting that women used 
the method for considerably longer periods. In 
contrast, they were fairly unanimous about the 
key reasons for discontinuation. Leading reasons 
were the inconvenience of returning to the facility 
every three months for re-injections, cost, and side 
effects, notably menstrual disturbances. Health care 
providers noted, for example, that many women 
who experienced heavy bleeding or irregular 
periods discontinued using injectable contraceptives, 
fearing that they had a serious disease. Those who 
experienced amenorrhoea were reported to fear that 
they were pregnant, and discontinued the method 
as a result. Additionally, because of cultural practices 
that forbid menstruating women from entering the 
kitchen or praying, women who experienced heavy 
bleeding or irregular menstruation discontinued using 
injectable contraceptives because it affected their 
ability to perform these regular tasks. Several also 
noted that weight gain and the long waiting time to 
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conception following discontinuation were additional 
reasons for discontinuing the method. Health care 
providers reported that method switching was 
evident among women who discontinued using 
injectable contraceptives for method-related reasons, 
and that the two methods to which women most 
commonly switched were tubal ligation and the 
IUCD.
Finally, health care providers were, for the most 
part, in favour of including injectable contraceptives 
in the national programme, in order that the basket 
of methods available to women would increase and 
provide women with greater choice. However, they 
argued strongly for certain prerequisites, such as 
comprehensive and sensitive counselling and effective 
follow up, for example. A few were sceptical; they 
believed that even with such improvements in the 
quality of services, few women in India would adopt 
or continue using injectable contraceptives because 
their side effects, notably menstrual disturbances, 
would discourage its use for both health and socio-
cultural reasons.
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This chapter highlights the lessons learned for 
programming from the findings of our study, drawn 
from the experiences and perspectives of women who 
had used injectable contraceptives, women seeking 
contraception, and health care providers who offer 
injectable contraceptives to women. The findings 
of the study suggest a number of priority areas for 
action.
Meet the demand for injectable 
contraceptives by including the method in 
the basket of contraceptives provided in 
public sector facilities
Findings highlight that there is considerable interest 
in adopting injectable contraceptives and clearly 
a demand for a safe and effective non-terminal 
method that allows women to control their fertility 
confidentially, that does not require daily attention 
and that does not require to be inserted. Relatively 
low continuation rates are associated with injectable 
contraceptives globally and the finding should not 
be interpreted as a lack of demand. Indeed, the 
finding that more than one-fifth of all injectable 
contraceptive users continued the method for 12 
months reiterates that there exists a demand for the 
method among certain groups of women. At the 
same time, evidence that many more discontinue 
injectable contraceptive use and immediately switch 
to a different method, thereby remaining protected 
against unintended pregnancy, suggests that injectable 
contraceptives play an important role in women’s 
overall contraceptive strategies. Expanding the basket 
of contraceptives available to women will, therefore, 
enhance women’s options and enable them to select 
the one whose features most suit their needs.
Include a component of injectable 
contraceptives in the training offered to a 
range of health care providers
Findings have suggested that health care providers 
who serve injectable contraceptive users may not be 
fully aware of the advantages and disadvantages of 
injectable contraceptives, the full range of side effects 
that are and are not associated with 
injectable contraceptives, and the counselling needs 
of potential users. It is important, therefore, to 
include a module on injectable contraceptives in 
the contraception-related training offered to a range 
of health care providers. For example, health care 
providers must be made aware of the appropriateness 
of injectable contraceptives for women who are 
recently delivered and lactating. Similarly, they 
should be trained to recognise that injectable 
contraceptives may satisfy the needs of women at 
different stages of the life cycle, for example, a newly 
delivered woman who wishes to space her next 
pregnancy, or a woman who is not medically eligible 
for an IUCD or does not want to have an IUCD 
inserted but is looking for a long-acting method. At 
the same time, they should be trained to appreciate 
that for some women, common side effects would 
likely be an intolerable disturbance in everyday life, 
and hence, should be equipped to counsel women 
so as to enable the woman to arrive at an informed 
decision about whether or not to adopt injectable 
contraceptives.
ChaPtEr 6
The way forward
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Given that a number of women from our study 
were drawn from rural areas, it is important that 
training for frontline health workers, such as ANMs, 
ASHAs and AWWs, should also include information 
about injectable contraceptives, how they function 
and where they can be obtained, as well as basic 
information about potential side effects and how 
these should be managed.
Expand awareness of injectable 
contraceptives at the community level
Findings have confirmed that many women seeking 
to adopt contraceptives were unaware of injectable 
contraceptives, and at the same time, although the 
method is not available through the programme, 
a sizeable number of women do indeed opt for it. 
It is important, therefore, that efforts are made to 
inform communities, and women in particular, about 
injectable contraceptives, how they function, their 
cost, and where they can be obtained, as well as 
basic information about potential side effects.
Improve the quality of care and 
counselling provided to injectable 
contraceptive users
Findings suggest a disconnect between the views 
of health care providers on the comprehensiveness 
of counselling provided and women’s views about 
the comprehensiveness of counselling received from 
health care providers with regard to injectable 
contraceptives. This disconnect highlights the need 
for health care providers to ensure that women are 
indeed making an informed choice, that they fully 
understand the implications of likely side effects for 
their life. Health care providers have acknowledged 
the importance of including husbands in the 
counselling session, and findings have confirmed 
that continuation beyond the first dose is indeed 
influenced by the role of the husband in decision-
making. Provided that the woman agrees, it is 
important that counselling includes both the woman 
and her husband and that both are made fully 
cognisant of possible side effects.
As far as counselling is concerned, health care 
providers must be trained to ensure that counselling 
encompasses the full range of side effects associated 
with injectable contraceptives, as well as the action 
that the woman should take in case these side 
effects are experienced; the need to ensure that 
the woman has understood the implications of the 
method proposed, including injectable contraceptives, 
must be emphasised. For example, women, and 
their husbands if present, must be informed that 
amenorrhoea, irregular menstrual cycles and heavy 
bleeding occur to large numbers of injectable 
contraceptive users, that some women may gain 
weight, and that return to fertility may be slower 
than in the case of other contraceptives. Counselling 
sessions must also make women feel supported in 
case side effects are experienced, and emphasise 
the appropriateness of follow-up visits and phone 
calls in case the woman has concerns. Our finding 
that continuation rates were significantly higher 
among women who were provided comprehensive 
counselling underscores the critical role that health 
care providers play in ensuring method satisfaction.
Make special efforts to inform injectable 
contraceptive users and potential users 
about health-related side effects
Menstrual disturbances and weight gain are 
common and well-known side effects of injectable 
contraceptives, and return to fertility is typically 
longer among women who discontinue using 
injectable contraceptives than other methods. Women 
considering use of the method must be supported 
in making an informed decision, given these 
three key concerns. Irregular prolonged bleeding, 
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amenorrhoea and/or heavy bleeding occur among 
most users of injectable contraceptives at some 
point while using the method, and women should 
be informed about this likelihood and the fact that 
side effects are typically not harmful. Although 
injectable contraceptives are a reversible method of 
fertility regulation, women also need to be informed 
that since the method is long-acting, it cannot 
easily be discontinued or removed from the body 
if a complication occurs or if pregnancy is desired. 
Counselling sessions should be supplemented by 
pamphlets and easy-to-read materials that highlight 
these side effects, emphasise that they are not 
harmful, and advise users about the action to take in 
case they are experienced.
Reduce barriers to accessing supplies
Findings have shown that 16 percent of all women 
who had discontinued using injectable contraceptives 
and between 12 percent and 28 percent of women 
who had discontinued using the method after various 
doses reported difficulty in accessing re-supplies. The 
leading access-related barrier was the inconvenience 
of accessing the facility every three months for 
re-injections. Long distances, limited freedom of 
movement and unavailability of an escort, and time 
spent in travelling to the facility for re-injections 
were significant deterrent to method continuation. 
Efforts are needed that enable women to obtain re-
injections closer to their homes and at reduced cost; 
the introduction of the method into the programme 
would go a long way in doing so.
Conclusion
In short, findings suggest that there is a demand for 
injectable contraceptives among women, and that 
both women and health care providers perceive a 
number of advantages associated with the method. As 
is well known, injectable contraceptives may not suit 
the lifestyle of many Indian women and our findings 
have confirmed that the method was adopted and 
was continued for one year or more, by relatively few 
women. Nevertheless, the fact that it was adopted 
by one in ten women seeking contraception, and 
was continued for one year or more by one in five 
women who adopted the method, reiterates that 
for a significant minority of women, its advantages 
exceed its disadvantages on balance. We conclude 
that there is indeed a demand for the method among 
this minority of women, and that the inclusion of 
injectable contraceptives in the basket of methods 
offered under the national programme, along with 
appropriate emphasis on health care provider training 
and on ensuring informed choice, will expand 
women’s contraceptive choices and help in ensuring 
their reproductive rights.
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